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CYTOMEGALOVIRUS INFECTION AFTER ORGAN
TRANSPLANTATION: AN INTRODUCTION
1.1 HUMAN CYTOMEGALOVIRUS: A HERPES VIRUS
The herpesviridae are a large group of double-stranded enveloped DNA viruses. More
than 150 members of the herpes family have been identified to date. In humans eight
different herpes viruses are known. The official names human herpes virus 1 till 5 are
seldom used and they are more usually known  by their  common  names: Herpes
Simplex Virus type 1 and type 2 (HSV), Varicella Zoster Virus  (VZV), Human
Cytomegalovirus (CMV) and Epstein Bar Virus (EBV). Human herpes viruses 6 till
8 have no other names.
Cytomegalovirus infections were first described in the beginning of the previous
century when the typical owl’s eye  intranuclear  inclusions were found by histo-
pathologists in tissues from fetuses stillborn following cytomegalic inclusion disease.
Long time the infection was thought to be of protozoan nature. In 1956 CMV was
isolated for the first time and the true nature of this infectious agent became clear.
The virus was given its name by Weller from the cytopathic effect produced in cell
culture [1].
1.2 BIOLOGY OF CYTOMEGALOVIRUS
CMV or herpes virus 5 has a typical  herpes virus appearance.  The  central  double
stranded DNA genome of about 235 thousand base pairs is surrounded by an icosa-
hedral capsid composed of 162 capsomeres. An area called the tegument surrounds
the capsid and is surrounded itself by a loosely applied envelope.  The  tegument is
constituted of about 20 proteins with pp65 (ppUL83) as major representative. The
pp65 is of special interest because it is used as a diagnostic tool  in the  pp65  anti-
genemia assay. In active infection pp65 can be found in the nuclei of a small fraction
of polymorphonuclear granulocytes. These granulocytes have  acquired the  pp65
from infected endothelial cells [2, 3]. Upon in vitro infection  the  pp65  protein  isChapter 1 2
transported to the nucleus of infected fibroblasts immediately after fusion of the
virion with the cell membrane. The protein has kinase activity and auto-phosphor yl-
ation capacity [4].
The entry of CMV in target cells has been investigated in vitro in fibroblasts, endo-
thelial cells and phagocytes [5]. First there is attachment  and fusion of the  virion
with the cell membrane. Glycoproteins of the  viral envelope  [5-11]  play a deter-
mining role in this process. Also HLA class I (Human Leukocyte  Antigen class I)
molecules are reported to have a role in viral entry [12]. The capsid moves to  the
nucleus and the process of transcription and translation  of early and late antigens
starts, following a very strict timetable [13, 14]. Due to especially the  cellular im-
mune response, infected cells will be destroyed and further replication and dissemina-
tion of the  virus will be stopped. The  virus comes in a stage of latency  and may
reactivate during a state of decreased immunity i.e. by the use of immunosuppressive
drugs. Especially the potent monoclonal drug OKT3 (Orthoclone  Muromonomab)
and the polyclonal antithymocyte globulin (ATG) are known as potent inducers of
CMV reactivation. This is probably mediated by  TNF-alpha  release  during for
example OKT3 treatment. TNF-alpha induces the transcription factor NF-kB thatIntroduction 3
causes enhancement of the major Immediate Early enhancer/promoter gen of CMV
[15].
1.3 CYTOMEGALOVIRUS AND THE IMMUNE SYSTEM
After primary CMV infection  CMV IgM antibodies are produced before IgG anti-
bodies and persist for a few months. CMV IgG antibodies are produced after  secon-
dary and primary infections and persist lifelong [16]. This persistence is the reason
that IgG antibodies are used as sign that the patient had CMV infection in the past.
Donor and recipient CMV serology determine the  risk of CMV infection  and the
type of infection after transplantation.  Primary infections are infections in the posi-
tive-negative donor-recipient combinations, and secondary infections or reactivation
in the neg-pos or pos-pos combinations. Whether CMV antibodies play an important
role in the defense against CMV is still unclear. The importance of  the  humoral
immunity is suggested by the clinical observation  that  without  humoral  immune
response the patient will not clear the virus. If  this  is caused by the  absence of
humoral response or by absence of cellular response  that  causes also absence of
humoral response by not functioning CD4 T helper cells remains unclear. Another
argument for a role of antibodies in the clearance of the virus is the effectiveness of
prophylactic administration of CMV immunoglobulin in seronegative recipients of
kidneys from seropositive donors in preventing morbidity and mortality associated
with CMV [17, 18]. The importance of the humoral immune response is also demon-
strated by the finding that CMV specific antibodies reduce the  generation  of pp65
positive granulocytes by inhibiting uptake of pp65  by granulocytes from infected
endothelial cells in vitro [3].
The cellular immune response by CD4 helper T-lymphocytes,  CD8 cytotoxic
T-lymphocytes and Natural Killer (NK) cells is important in the defense  against
Cytomegalovirus [19, 20, 21]. But Cytomegalovirus has developed several mechan-
isms to evade cellular immune response [22, 23]. For example the virus can prevent
HLA class I loaded with viral peptides to be delivered to the cell surface. This makes
the infected cell invisible to CD8 cytotoxic T-lymphocytes. Also the virus encodes
a glycoprotein homologous to class I MHC antigens to prevent attack by NK cells.
CMV has been associated with increased subsequent risk for acute rejection  in
kidney and other solid organ transplant recipients [24]. Whether the risk is conferred
by the reduction of immunosuppressive medication used to treat CMV infection or
is a direct immunomodulating effect of the virus, is not known. Another possibilityChapter 1 4
is that CMV infection does not predispose to rejection but that rejection predisposes
to active CMV infection.
In contrast Cytomegalovirus can enhance suppression of the immune response. CMV
predisposes  to  subsequent  opportunistic  infections  like  Pneumocystis  Carinii
pneumonia (PCP) or fungal infections. Another argument for immunosuppression
by CMV could be that CMV and for example HSV or VZV infections are often seen
simultaneously.
1.4 DIAGNOSIS
CMV monitoring can be done in various ways. In our center  pp65  antigenemia is
detected in preparations of granulocytes from peripheral blood. These granulocytes
are reacted with monoclonal antibodies  against pp65  (phosphoprotein  ppUL83)
followed by immunoperoxidase staining. The phagocytic activity of the granulocyte
has led them to ingest this protein from virus-infected cells. Maybe the  protein  is
derived from dense bodies, which consist almost entirely of pp65 and probably are
products of defective viral replication [25]. Other methods of virus  detection  in
peripheral blood are viral DNA detection by polymerase chain reaction (PCR), viral
mRNA detection by NASBA, conventional cell culture or detection of early antigen
fluorescent foci in cultures.
1.5 HUMAN CYTOMEGALOVIRUS CLINICAL ASPECTS
Cytomegalovirus infection comprises the whole lifespan  of  humans.  It  can  be
acquired even before birth. The incidence of seropositivity  increases with age. Al-
most 60-90% of the dialysis patients is  seropositive,  depending on  age, and for
example socioeconomic circumstance [26]. The virus can be acquired by intimate
contact between mother and child, or from child to child in daycare centers, by sexu-
al contact, by blood transfusion (leukocytes) and by organ transplantation. Latently
infected monocytes and endothelial cells could be the origin of the virus after kidney
transplantation of a seropositive kidney to  a seronegative recipient  [27-32].  The
incubation period is between 4 and 8 weeks. In the general population most CMV in-
fections will not be noticed because they  are asymptomatic  or only cause flu-likeIntroduction 5
symptoms. Also when the infection gives rise to a mononucleosis like syndrome the
diagnosis of CMV probably will not be made.
During the last three decades due to the increasing possibilities of organ trans-
plantation cytomegalovirus has become a frequent infection in transplanted patients
and the diagnosis and treatment of the virus have become important issues. Nowa-
days incidence of CMV infection (not disease) is about 60 % of patients at risk in our
center (this thesis chapter 2).
The majority of transplant patients with CMV infection diagnosed by for exam-
ple a routinely performed pp65 antigenemia assay remain asymptomatic. They have
CMV infection but no CMV disease. Nevertheless in these patients without clinical
symptomatology subtle organ dysfunction can be demonstrated (this thesis).
If the infection is symptomatic most patients develop a flu like syndrome with
fever,  arthralgia,  and  in  the  blood  tests  leukocytopenia,  thrombocytopenia  and
elevated liver transaminases. In particular in patients with long lasting CMV infec-
tion all organ systems can be involved. For example gastroenteritis, ulcers, vasculitis,
pneumonitis and retinitis are seen.
The incidence, course and severity of CMV infection differ in the different fields
of organ transplantation. This is mainly  due to  the  different  kinds of  immuno-
suppressive regimen. In the European Mycophenolate Mofetil (MMF) Cooperative
Study the incidence of CMV disease was 36% for patients  receiving a high dose of
MMF (3 gram/day) compared with 8% for the patients who received either placebo
or 2 gram/day MMF) [33].  We  also found an  increase in  CMV infections  after
changing our immunosuppressive regimen (this thesis chapter 2).
In  the  long  run  chronic  transplant  dysfunction  (‘chronic  rejection’)  and
atherosclerosis are important threats to the transplanted patient. CMV might  be
important in the development of atherosclerosis as is for example demonstrated by
the association of prior CMV infection and the risk of restenosis after  coronary
atherectomy after angioplasty [34, 35, 36]. Upregulation of adhesion molecules such
as VCAM-1 might play a role in the development of vascular sclerosis [37,  38].
VCAM-1 would facilitate adhesion of leucocytes to the endothelial lining and could
play a role in the process of endothelialitis and the forming of plaques.
Evidence for endothelialitis in patients comes from biopsies but also from peri-
pheral blood samples from transplanted patients. During severe CMV infection cyto-
megalic endothelial cells can be demonstrated in peripheral blood [39, 40]. These
cytomegalic cells have a diameter of 35-45 mm and show the characteristic owl’s eye
appearance. CMV proteins of all replication stages could be detected proving that
these cells are late stage CMV infected cells. The large size of these CEC compared
to normal endothelial cells is remarkable. The  CEC could obstruct capillaries andChapter 1 6
cause organ dysfunction by diminished perfusion of these organs (chapter 3, 4, 5 and
6).  Another  role  of  CEC  in  the  pathogenesis  of  CMV infection  could be  the
dissemination of the virus via the blood stream.
Another interesting  finding is that  CMV stimulates smooth  muscle cells to
migrate and proliferate after infection [41, 42, 43]. These smooth muscle cells play
a role in the development of atheroma.
Cytomegalovirus is one of the risk factors for chronic transplant  dysfunction [44,
45]. Probably this explains that CMV infection has been associated with  reduced
patient and graft survival rates [46, 47]. For example among 47.146 patients in the
UNOS registry, kidneys from CMV positive donors demonstrated approximately 4%
lower graft survival rates at 3 years after  transplantation,  compared with kidneys
from CMV-negative donors [47]. In the study of Humar et al. [45]  CMV is a risk
factor for chronic allograft rejection but only in the presence of acute rejection. The
combination of acute rejection  and CMV infection  is associated with a higher in-
cidence of chronic rejection than acute rejection without CMV infection. Interesting
is that we demonstrated increased levels of circulating endothelial cells especially in
patients with CMV infection after a period of acute rejection.  This illustrates that
the combination of CMV infection and acute rejection  gives rise to  more chronic
transplant dysfunction. Keeping this in mind chronic transplant dysfunction can be
seen as a vascular pathology just like atherosclerosis (this thesis chapter 9 and 10).
Another hypothesis is that CMV infection may mimic or predispose  to  late
rejection. In this hypothesis chronic transplant dysfunction is explained by immuno-
logical mechanisms. Possible mediators of CMV related rejection  are for example
intracellular adhesion molecule-1 (ICAM-1) and lymphocyte functioning antigen-3
(LFA-3) which are upregulated during CMV infection [48, 49]. Also the transcription
and expression of interleukin-2 (IL-2) and the IL-2 receptor are upregulated by CMV
gene products [50]. These  products  can  also  prevent  the  inhibitory  effect  of
cyclosporine on IL-2 gene transcription [51]. Other authors found that CMV is able
to stimulate alloreactive cytotoxic T-cells [52].
In both the vascular and the immunological view on chronic transplant dysfunc-
tion the endothelium plays an important role. Cytomegalovirus infecting and upregu-
lating endothelial cells causing chronic transplant  dysfunction, atherosclerosis and
disturbed organ perfusion will be discussed in this thesis.
 Last but not least CMV infection can be seen as a risk factor for post transplant
lymfoproliferative disease [53].Introduction 7
1.6 CYTOMEGALOVIRUS THERAPY
Only using seronegative donors prevents CMV infection, but shortage of donors will
not allow this strategy. Matching for CMV prevents primary CMV infections: sero-
negative kidneys are reserved for seronegative recipients. The point is that as a result
of CMV matching, HLA matching will be worse. Further this approach will lead to
an increase in waiting time. Eventually graft survival is important and it remains a
question how CMV matching affects graft survival [46]. Using seronegative  or
leukocyte free blood products in seronegative patients who have been transplanted
with a seronegative organ is important to prevent CMV infection.
Ganciclovir and foscavir are the two antivirals used in the  Netherlands against
CMV nowadays. Ganciclovir has to be phosphorylated by the product of the UL97
gene of CMV [54] and then the triphosphate inhibits the viral DNA polymerase
(UL54). Foscavir inhibits viral replication by noncompetitively blocking the pyro-
phosphate binding site of viral DNA polymerase, preventing cleavage of pyrophos-
phate from deoxynucleoside triphosphate and elongation of the  viral DNA chain.
Unlike ganciclovir, foscavir does not require viral thymidine kinase for activation.
As mentioned earlier antibody titers are useful in assessing the risk for CMV infection
at the time of transplantation,  by determination  whether the  donor and recipient
were infected with CMV previously. This risk stratification  allows selective use of
antiviral therapy to prevent CMV [55, 56]. Selective prophylactic  treatment  of
high-risk patients avoids unnecessary  adverse reactions  and the  development  of
resistance  [57]. In  our  center  no  prophylactic  therapy  is  used  after  kidney
transplantation.  Preemptive  therapy  in  patients  with  a  positive  CMV  pp65
antigenemia but still without disease has been adopted in our center last years. The
preemptive  strategy aims at eliminating CMV infection prior to its manifestation as
active disease. The advantage of preemptive therapy is to target patients at risk for
CMV disease and eliminate  unnecessary  treatment.  The  disadvantage  of  not
preventing CMV infection but treating it very early (preemptive approach) could be
not preventing indirect  damage of  the  viral  infection  like the  subclinical organ
dysfunction and chronic transplant dysfunction. Most centers consider tapering of
immunosuppression as the first line  and  cornerstone  of  management  of  CMV
infection after organ transplantation. For instance, reducing the dose of Cellcept has
proven to be helpful to recover from CMV infection (this thesis chapter 2).Chapter 1 8
1.7 SCOPE OF THIS THESIS:  CYTOMEGALOVIRUS  AS  A  SYSTEMIC
INFECTION IN THE RENAL TRANSPLANT RECIPIENT
We know from earlier studies that CMV  infection  after  organ  transplantation
involves infection of endothelial cells. In this thesis the role of CMV endothelialitis
in the pathophysiology of CMV infection is explored in different organ systems. The
possible relation between on the one hand organ dysfunction and on the other hand
viral load, circulating endothelial cells and other signs of endothelial damage was
studied.
Cytomegalovirus disease is seen less last  years  due to  better  diagnostic and
therapeutic tools. On the contrary the incidence of Cytomegalovirus infection diag-
nosed in our center by a positive CMV pp65 antigenemia assay is increasing (chapter
2). We demonstrated a longer duration and higher levels of pp65  positive granu-
locytes in peripheral blood (pp65 antigenemia assay) after  introduction  of myco-
phenolate mofetil (Cellcept). The higher incidence especially of the secondary in-
fections, and the prolonged periods of higher viremia could  be important  in  the
development of chronic transplant dysfunction and atherosclerosis. The disturbance
of organ function in clinical asymptomatic patients described in the following chap-
ters (lung, intestines), and the unknown long-term consequences of these subclinical
effects, could be the importance of the increased incidence of CMV infections.  In
chapter 3 we describe that the gastrointestinal  barrier is not  intact  during cyto-
megalovirus infection. In chapter 4 we hypothesize that cytomegalic endothelial
cells that may plug into the capillary bed, cause the pulmonary dysfunction found by
van Son et al. in patients with cytomegalovirus infection. However, we found that
the mechanism is more complicated than only plugging of cytomegalic endothelial
cells. In chapter 8 we describe a patient with a long period of positive antigenemia
and the development of a chronic inflammatory demyelinating polyneuropathy after
kidney  transplantation.  We  speculate  about  the  pathogenesis  of  chronic
inflammatory demyelinating polyneuropathy  in  kidney  transplant  recipients.  In
chapter 9 cytomegalic and non-cytomegalic circulating endothelial cells in kidney
transplant recipients with CMV infection were studied. In chapter 10 we found lower
thrombocyte counts in patients with CMV infection after liver transplantation and
discuss the relation between CMV infection, the endothelium and thrombocytes. In
chapter 12 we try to give an answer to one of the central questions in this thesis: is
CMV still important in the transplant clinic? Do we have to be  afraid  of  the
smoldering asymptomatic cytomegalovirus infections? Is cytomegalovirus infection
a vanishing or changing problem?Introduction 9
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CYTOMEGALOVIRUS INFECTION IN RENAL
TRANSPLANTATION: A SINGLE CENTER REPORT
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ABSTRACT
Background. In this retrospective single center study we have evaluated the relation
between the immunosuppressive regimen and the incidence and characteristics of
cytomegalovirus (CMV) infection in the setting without  CMV prophylaxis  from
1989 through 1998.
Methods. All (470) first cadaveric renal transplantations  in nonsensitized (PRA <
60%) patients were analyzed. Immunosuppression  consisted  of  cyclosporine  A
(Sandimmune) and prednisolone from 1989  through 2-1993  (S; 189  patients),  of
cyclosporine microemulsion (Neoral) and prednisolone from 3-1993 through 5-1997
(N; 200 patients) and of mycophenolate mofetil, Neoral and prednisolone from 5-
1997 until 1998 (M; 81 patients). CMV pp65-antigenemia was measured routinely
at least once weekly from day 10 till 12 weeks after transplantation or until pp65-
antigenemia became negative. No CMV-prophylaxis was given.
Results. By changing from Sandimmune to Neoral and by adding mycophenolate
mofetil, respectively, we observed a higher frequency of especially secondary CMV
infections (S vs. N vs. M respectively 28 vs. 50 vs. 63%, P = 0.026;  S vs. N, P =
0.027; S vs. M, P = 0.015;  and N vs. M n.s.). The  CMV infections  lasted longer
(median duration antigenemia S vs. N vs. M respectively  3 vs. 5 vs. 7 weeks, P =
0.0003; S vs. N, P < 0.002; S vs. M, P < 0.001; and N vs. M, P < 0.05).  Viral load
was higher in M (median maximal pp65-antigenemia S vs. N vs. M respectively 19
vs. 14.5 vs. 73, P < 0.01, S vs. N, n.s.; S vs. M, P < 0.001; and N vs. M, P < 0.01).
Conclusions. The use of Neoral and the addition of mycophenolate mofetil  caused
significant changes in the incidence, duration and viral load of CMV infections.Effects of immunosuppressive regimen 19
2.1 INTRODUCTION
Over the past decades the immunosuppressive regimen used in transplantation  has
changed considerably. In the seventies immunosuppression after renal transplanta-
tion consisted of azathioprine and prednisone. The introduction of cyclosporine im-
proved graft survival in the eighties. To date, mycophenolate mofetil and tacrolimus
are fully integrated in most immunosuppressive protocols and cyclosporine standard
formulation (Sandimmune, Novartis) has been converted to a microemulsion formu-
lation (Neoral, Novartis) in most European centers. Also rapamycin is  currently
under study in clinical transplantation  and a number of new more specific mono-
clonal agents are replacing older polyclonal antisera.
The availability of all these new immunosuppressive drugs enables us to  design
rational and perhaps more individualized combinations to prevent acute and chronic
rejection and, very important, may minimize the risks of the sequelae of immuno-
suppression: malignancy and infection.  Also, cardiovascular side effects and pred-
nisone-induced bone disease have become distinguished complications in the long
term. Until today only few well-controlled trials have compared different immuno-
suppressive regimens as regards their long-term side effects. Especially no detailed
virological data are presented in the literature concerning the different  immuno-
suppressive regimens. In the  majority  of predominantly  multicenter  studies cyto-
megalovirus (CMV) infection is scored as an ‘on-off’ phenomenon without enumera-
tion of detailed virological data. Furthermore data are lacking for asymptomatic pa-
tients and the interpretation of the studies is difficult owing to different prophylactic
protocols for CMV.
However, CMV is one of the most frequent infectious complications  after
kidney transplantation. It causes severe morbidity and even mortality. If CMV infec-
tion causes disease most patients have a so-called self-limiting CMV syndrome cons-
isting of spiking fever, arthralgia, leukocytopenia, thrombocytopenia, and elevated
serum liver enzymes.
Many CMV infections after kidney transplantation,  however, remain asymp-
tomatic and in our center are recognized by routinely performed pp65-antigenemia
assay [1, 2] to be confirmed by a serum-response later [3]. Nevertheless, we have
demonstrated that in ‘asymptomatic’  kidney transplant  patients  subclinical organ
dysfunction can be detected during CMV pp65-antigenemia.  This dysfunction was
associated with an increased intestinal permeability and a decrease in pulmonary dif-
fusion in kidney transplant recipients with positive antigenemia assays but without
symptoms [4-6]. The impact of these manifestations of CMV infection  especially
on long-term function has yet to be established.Chapter 2 20
Cytomegalovirus is suspected to play a role in the pathogene sis of atherosclerosis
also in non-transplanted patients [7]. Endothelial damage caused by the viral infec-
tion might be an important factor in the  pathophysiology  regarding the  suggested
connection between atherosclerosis and cytomegalovirus infection. In this respect
the hypothesis that cytomegalovirus can cause  endothelial  damage in  the  trans-
planted organ leading to chronic transplant dysfunction [8-16] is particularly inter-
esting.
In this retrospective single center study we have evaluated the relation between
the immunosuppressive protocol used and incidence, duration and viral load of cyto-
megalovirus infections in first cadaveric kidney transplant procedures in our institu-
tion from 1989 through 1998.
2.2 MATERIALS AND METHODS
2.2.1 Study  design
From January 1989 through July 1998, 721 patients were transplanted in our center.
Of those, 470 patients received a first transplant  and followed our standard im-
munosuppressive protocol consisting of Cyclosporine standard formulation (Sandim-
mune, Novartis) and prednisolone from January 1989 through  February 1993  (S
group). From March 1993 through May 1997 cyclosporine microemulsion formula-
tion (Neoral, Novartis) and prednisolone (N group) were used. From May 1997 until
now mycophenolate mofetil (Cellcept, Roche), Neoral, and prednisolone were admi-
nistered (M group). Patients on different immunosuppressive  regimens were excluded.
Also excluded were patients with more than 60% panel  reactive  HLA-antibodies
(primary triple therapy or induction therapy  with OKT3  or ATG). Living related
kidney  transplant  recipients  on  primary  triple  therapy  with  azathioprine  and
Sandimmune were excluded. Also excluded were patients participating in the  Euro-
pean Mycophenolate Mofetil Cooperative Study [17] (Sandimmune instead of Neoral
in combination with mycophenolate mofetil and prednisolone). All 470  patients
were divided into three groups according to the three different immunosuppressive
regimens used during the past ten years. All pertinent data of the three groups espe-
cially those regarding CMV infections were analyzed in this study.Effects of immunosuppressive regimen 21
2.2.2 CMV  definitions
All primary and secondary CMV infections were studied.
Primary CMV infections were defined as seronegative  recipients  receiving a
transplant from a seropositive donor (pos-neg serology combinations for donor-reci-
pient) and subsequently became positive in the pp65-antigenemia assay and devel-
oped an anti-CMV IgM and subsequently IgG response. The  incidence of primary
infections was defined as the percentage of primary infections in the patients at risk
for primary infections: pos-neg combinations.
Secondary CMV infections were defined as seropositive recipients who developed
a positive pp65-antigenemia, irrespective of their serological response (pos-pos or
neg-pos serology combinations). The incidence of secondary infections was defined
as the percentage  of  secondary  infections  in  the  patients  at  risk for  secondary
infections: pos-pos and neg-pos combinations. The neg-neg combinations with no
risk to develop CMV infection were not included in the analysis. No CMV-prophyl-
axis with ganciclovir, acyclovir or immunoglobulins was used. Ganciclovir i.v. was
given for CMV-disease or preemptively during antirejection therapy  when the  yet
asymptomatic patient was positive in the pp65-antigenemia assay.
2.2.3 CMV  diagnostics
Diagnosis of active CMV infection was made using the CMV pp65-antigenemia assay,
as described by Van der Bij et al. [1] and reviewed by Chou [18] and by Ljungman and
Griffiths [19] during the Fourth International CMV Workshop  (Paris, 1993).  The
quantitative antigenemia  assay correlates  well with viral  load and CMV induced
disease [2]. Thus a higher antigenemia reflects the condition of a higher viral load in
this report. Recently an attempt to standardize the CMV pp65-antigenemia assay has
been proposed by our group [20]. Briefly, peripheral blood leukocytes were isolated,
cytocentrifuged and incubated with a mixture  of  monoclonal  antibodies directed
against a 65 kDa CMV antigen, followed by immunoperoxidase staining. The number
of antigen-positive cells and total number of leukocytes  were counted  on  two
different cytospots and results were expressed as number of pp65 positive cells per
50.000 leukocytes. Antigenemia assay was performed at least once weekly starting
on  postoperative  day  10  until  12  weeks after  transplantation  or  until  pp65-
antigenemia became negative. In all the patients antigenemia was followed by either
seroconversion or significant rise in CMV IgG antibodies. The  IgM and IgG CMVChapter 2 22
antibodies were measured quantitatively by ELISA using late stage CMV-infected
fibroblasts as antigens [3].
2.2.4 Rejection  treatment
Rejections were diagnosed clinically by a rise in serum creatinine and sodium reten-
tion without a clear other cause, and were treated with a pulse therapy  of methyl-
prednisolone 1 gram i.v. on three consecutive days. The majority of clinical rejec-
tions were confirmed by biopsy and diagnosed according to the Banff criteria [21].
Patients  with  a  steroid-resistant  interstitial  rejection  were  treated  with
antithymocyte immunoglobulin (rabbit-ATG, Merieux, Lyon, France), five times 4
mg/kg, i.v. every other day. When vascular rejection was found plasmapheresis was
added to the ATG treatment protocol on alternate days.
2.2.5 Statistics
The distribution of patients among the three different groups was  tested  using
contingency tables (c
2-test) for multiple groups and c
2-test for two groups as a post-
test if P < 0.05. The three groups were analyzed using ANOVA or non-parametric
analysis  of  variance:  Kruskal-Wallis  test.  Tukeys  test  or  Dunn’s  Multiple
Comparison test was used as post-test if P < 0.05.
2.3 RESULTS
2.3.1 Patient  characteristics,  donors,  matching  per  treatment  group
Patient and donor characteristics of all evaluated first cadaveric kidney transplant
recipients treated with standard immunosuppression in our center from  1989  till
1998 are given in table 2.1. In the N and M group there  were more female donors
than in the S group (S vs. N vs. M in percentage females respectively,  44, 68 and
62%, P < 0.0001; S vs. N, P = 0.0001; S vs. M, P = 0.0073; and N vs. M, n.s.). The
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M in median hours, 25 vs. 23 vs. 19h, P < 0.0001; S vs. N, P < 0.01; S vs. M, P <
0.001; and N vs. M, P < 0.05). The M group consisted of fewer well-matched kidneys
for HLA-DR compared to the N and S group (S vs. N vs. M in mean mismatches for
HLA-DR 0.47 vs. 0.28 vs. 0.54, P < 0.0001; S vs. N, n.s.; S vs. M, P < 0.001;  and
N vs. M, P < 0.01).
2.3.2 CMV  infection:  incidence,  first  day,  duration  and  maximal
antigenemia
The incidence of positive pp65-antigenemia as indication for active CMV infection
in the donor-patient combinations at risk for CMV (pos-neg, pos-pos and neg-pos
combinations) was 35% in the S group compared to 53% in the N group and 64% in
the M group (P = 0.041; S vs. N, P = 0.049; S vs. M, P = 0.020; N vs. M, n.s., table
2.2, figure 2.1a). The median time between the  transplant  operation  and the  first
positive antigenemia assay did not differ between the groups (respectively 4, 5 and
4.5 weeks: n.s.).
However, the median duration of positive pp65-antigenemia  was found to  be
significantly longer after the change of the immunosuppressive protocol from S to
N and M, respectively (median duration S vs. N vs. M respectively 3, 5 and 7 weeks,
P = 0.0003; S vs. N, P < 0.002; S vs. M, P < 0.001; and N vs. M, P < 0.05, table 2.2,
figure 2.2b). In addition the  median maximal viral load measured as the  maximal
reached CMV pp65-antigenemia level, was higher in the M group compared to  the
N and S group (S vs. N vs. M respectively 19, 14.5 and 73, P < 0.01; S vs. N, n.s.; S
vs. M, P < 0.001; and N vs. M, P < 0.01, table 2.2, figure 2.2a).
2.3.3 Primary versus secondary infection, IgG and IgM response
The distribution of CMV negative recipients at risk for primary  infection  and of
seropositive recipients at risk for secondary infection did not differ  significantly
between the three groups (table 2.3).  The  increase in incidence in CMV infection
after changing from Sandimmune to Neoral was owing to an increase in secondary
infections (S vs. N vs. M respectively 28, 50 and 63%, P = 0.026; S vs. N, P = 0.027;
S vs. M P = 0.015; and N vs. M, n.s., table 2.2, figure 2.1c).Chapter 2 26Effects of immunosuppressive regimen 27Chapter 2 28
The median maximal pp65-antigenemia level in the primary infections was signi-
ficantly higher in the M group than in the S group (S vs. N vs. M respectively 68,
150.5 and 295, P = 0.007; S vs. N, n.s.; S vs. M, P < 0.01; and N vs. M, n.s., table
2.4). Also the median duration of positive antigenemia was significantly longer in
primary infections when protocols changed from S to N and M (S vs. N vs. M
respectively 4.5, 9 and 12 weeks, p = 0.012; S vs. N, P < 0.05; S vs. M, P < 0.05;
and N vs. M, n.s., table 2.4).
In patients with a secondary infection the median maximal pp65-antigenemia
level was significantly higher in the M group compared to the N group (S vs. N vs.
M respectively, 3.5, 2 and 16, P = 0.026; S vs. N, n.s.; S vs. M, n.s.; and N vs. M, P
< 0.01). In patients with secondary infections the median duration of positive anti-
genemia was significantly longer in M compared to S (S vs. N vs. M respectively, 3,
4 and 5 weeks, P = 0.0017; S vs. N, ns; S vs. M, P < 0.01; and N vs. M, n.s., table
2.4).
In both primary and secondary infections no difference in the time interval be-
tween transplant and start of positive antigenemia was seen.
2.3.4 Rejection  episodes  and  CMV  infection
The number of antirejection treatments was similar in all three  groups. Standard
antirejection treatment with methylprednisolone was given in respectively  42, 42
and 41% in the S, N and M group (n.s.). ATG treatment was required in respectively
16, 22 and 16 % of the patients in the three groups (n.s.). When patients without a
rejection were analyzed, also a significantly higher incidence of  secondary  CMV
infection, coinciding with the change immunosuppressive protocol was found (S vs.
N vs. M respectively, 18, 41 and 55%, P = 0.04; S vs. N, P = 0.031;  S vs. M, P =
0.022; and N vs. M n.s.).Chapter 2 30
2.3.5 Symptomatology
In this study the majority of patients with a positive antigenemia assay were asymp-
tomatic or had a viral syndrome consisting of malaise, fever and arthralgia. Tissue
invasive CMV, e.g. clinical CMV pneumonitis or colitis was not seen in this cohort
of patients studied and has been a rare observation in our center. This is most likely
due to the frequent and routine control of pp65-antigenemia and preemptive use of
ganciclovir during rejection treatment in patients with positive antigenemia.
2.3.6 Antiviral  medication
The use of ganciclovir during CMV infection  was increased significantly in the  M
group compared to the other two immunosuppressive protocol groups (S vs. N vs. M
respectively, 21, 31 and 55 %, P = 0.0021; S vs. N, n.s.; S vs. M, P = 0.0007; and N
vs. M, P = 0.009).
No differences were found as regards the  treatment,  with acyclovir given for
other reasons than CMV in patients with CMV infection (respectively, 8%, 9% and
11% for S, N and M, n.s.).
2.4 DISCUSSION
This retrospective  single-center analysis reports  on the  effects of three  different
immunosuppressive protocols on the incidence,  duration  and viral  load of  CMV
infection, over a period of almost 10 years, without any form of CMV prophylaxis.
This study reveals interesting and sometimes unexpected findings. In contrast  to  a
number of reports, we found that not the introduction of mycophenolate mofetil but
the introduction of Neoral, a few years earlier, has been mainly responsible for the
increase in CMV infections at our center. Particularly, an increase in secondary CMV
infections was observed after introduction of the Neoral formulation of cyclosporine.
No significant higher incidence of primary infections was seen although a longer
duration of this type of infection was observed. The addition  of  mycophenolate
mofetil (the  M group) did not  result in a further increase in the  number of CMV
infections. However, after the introduction of mycophenolate mofetil infections
became more prolonged than in patients treated only with Neoral and prednisolone.Effects of immunosuppressive regimen 31
Also, a striking increase in viral load was found after  mycophenolate  mofetil  was
added to our immunosuppressive  protocol.  The  period  between  the  transplant
operation and appearance of the virus did not differ between the three groups. The
observed increased incidence of  CMV infections,  the  longer  duration  of  CMV
infections, as well as the higher viral load after changing the immunosuppressive
protocol was not owing to  a more frequent use of potent  antirejection  treatment
with ATG, or owing to differences in cyclosporine trough-levels in the three  study
groups. In addition an increased incidence of CMV infection  was found in patients
who did not experience any rejection episode. The increased incidence could not be
explained by differences in use of antiviral drugs in the three study groups.  In
previous studies of Neoral and  prednisolone  vs.  Sandimmune and  prednisolone
treatment after renal transplantation a reduction of rejection episodes in the Neoral
group has been reported. This has been explained by the more stable and effective
immunosuppression of Neoral because of better absorption [22-24]. In these studies
CMV infections have not been considered in great detail. We speculate that  more
effective immunosuppression by Neoral compared with Sandimmune can explain the
increase in CMV infections. A recent report by  Ter  Meulen et  al. confirms  our
findings: no increase in the incidence of primary CMV infection was found by adding
mycophenolate mofetil to the cyclosporine-based immunosuppressive protocol [25].
More CMV-disease was seen in the patients treated with mycophenolate mofetil. The
authors suggest a delayed immune response due to  the  mycophenolate  mofetil
treatment that may have caused more symptomatic disease. However no information
is given concerning patients with a secondary infection  and the  diagnosis of CMV
infection concerns only serological data and no data of the viral load was presented
[25].
In this study we demonstrate  that  the  difference in frequency of CMV pp65-
antigenemia is due to an increase especially in the number of secondary infections
and not primary infections. The change  of  our protocol  from  Sandimmune and
prednisolone to Neoral and prednisolone and to Neoral, prednisolone and  myco-
phenolate mofetil, however, has changed the  primary  infections  ‘phenotypically’
since a longer duration of primary infections was observed.
The majority of the CMV infections  observed were asymptomatic  or charac-
terized by only mild symptoms such as fever and arthralgia. No severe CMV disease
was seen in the patients studied. Nevertheless, even asymptomatic CMV infections
can be clinically important long-term owing to their possible association with athero-
sclerosis and chronic transplant dysfunction [7-16]. Longer duration of this type of
smouldering CMV infection could potentially  be more  atherogenic  because of  a
prolonged endothelialitis and subsequent contribution to chronic transplant dysfunc-Chapter 2 32
tion. We have previously demonstrated the presence of cytomegalic (CMV-infected)
endothelial cells (CEC) and non-CMV infected endothelial cells (EC) in the blood of
renal  transplant  recipients  with  CMV  infection  [26].  Furthermore  we  showed
increased levels of Von Willebrand Factor (VWF) and s-VCAM (soluble vascular cell
adhesion molecule) to be markers of endothelial damage during CMV infection [27].
In patients with a CMV infection following a rejection episode we found significant
more endothelial damage as indicated by higher levels of CEC, EC, VWF and s-
VCAM.   
Our study was not designed to investigate the  impact  of  the  three  different
immunosuppressive protocols on the incidence of rejection. It was surprising that  no
difference in the incidence of rejection was found. This contrasts with the literature
where a decrease in incidence of rejection was shown by changing from Sandimmune
to Neoral and mycophenolate  mofetil  respectively  [17, 23, 28, 29]. However by
adding mycophenolate mofetil no changes in graft survival after  three  years were
found by different authors [30, 31]. A possible explanation that correlates with our
findings is that more prolonged exposure to  CMV might give us a clue. Beneficial
effects to reduce the development of  chronic  transplant  dysfunction  with fewer
rejections might be counteracted by unwanted effects caused by increased immuno-
suppression resulting in prolonged CMV viremia. Also mycophenolate  mofetil  has
been  claimed  to  have  antiproliferative  activity  on  smooth  muscle  cells  [32]
explaining the possible protection against chronic rejection in a rat model for kidney
[33] and in heart transplantation in baboons [34]. In human renal transplantation,
however,  such  a  positive  effect  of  mycophenolate  mofetil  has  not  yet  been
established.  We  conclude  that  the  change  of  the  immunosuppressive  regimen
switching  from  Sandimmune  to  Neoral  and  adding  mycophenolate  mofetil  is
accompanied by an increased incidence of secondary CMV infections in the Neoral
group. A higher and more prolonged CMV viremia  is observed especially in  the
mycophenolate mofetil group. Although the majority of these infections remain
asymptomatic, the perseverance of viral load results in extended endothelial damage
and  might  contribute  to  the  development  of  chronic  transplant  failure  and
atherosclerosis.Effects of immunosuppressive regimen 33
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ABSTRACT
Cytomegalovirus (CMV) infections in  renal  transplant  recipients  can  affect  the
gastrointestinal tract, but significant clinical manifestations are seldom seen.  We
hypothesize that subclinical involvement of the gastrointestinal tract may be quite
frequent during CMV infection.  In  order  to  study  this  we measured intestinal
permeability by calculating the urinary lactulose mannitol (LM) excretion ratio after
oral administration of lactulose and mannitol (normal <  0.030)  in  patients  with
symptomatic  and  asymptomatic  CMV  infection.  A  total  of  111  patients  were
enrolled into the  study, 104  of them  were tested on postoperative  day (pod) 10.
Twenty-nine patients developed CMV infection, 12 of them could be studied with the
permeability test (median pod 40). Another  nine patients  without CMV infection
were also studied at day 40 and served as controls.  The  LM  ratio  increased sig-
nificantly during CMV infection compared to measurements before active infection
(median 0.060 vs. 0.030, P < 0.01), and was significantly higher during the infection
than in the control group (median 0.007, P < 0.01). No correlation could be found
between the LM ratio and viral load, humoral response to the virus,  or  sympto-
matology of infection. We conclude that an increased intestinal permeability is found
in a substantial number of patients with an active,  albeit  asymptomatic,  CMV
infection after renal transplantation.  Pathophysiological  mechanisms and clinical
implications remain speculative but will be subject to further study.Increased intestinal permeability 41
3.1 INTRODUCTION
Cytomegalovirus infection is the most frequent infectious complication after renal
transplantation. Although CMV infections after renal transplantation are frequently
seen, a substantial number of them are asymptomatic. When CMV infection causes
disease most patients exhibit a so-called self-limiting CMV syndrome consisting of
spiking fever, arthralgia, leukocytopenia, thrombocytopenia, and  elevated  serum
liver enzymes. Less common manifestations involve the gastrointestinal tract, the
lungs, the eyes, the kidney, the heart and the nervous system. Clinical manifestations
of gastrointestinal involvement include ulcerative lesions anywhere along the gastro-
intestinal tract, intestinal pneumatosis [1], pancreatitis and hepatitis.
We hypothesize that there is  frequent  subclinical organ  involvement  during
CMV infection in renal transplant patients.  This would be in accordance with the
systemic nature of this type of infection.  For  example  van  Son et  al. [2]  have
already demonstrated that when subjected to sensitive pulmonary  function  tests, a
majority of patients with an active CMV infection have pulmonary dysfunction,
even  without  pulmonary  symptoms.  Thus  far  subclinical  involvement  of  the
gastrointestinal tract during CMV infection has not been studied.
The epithelium of the gastrointestinal tract has important transport functions,
but the barrier function with respect to luminal molecules is at least as important.
Intestinal permeability relates to the barrier function and the permeation of marker
molecules is used to measure the permeability. Most intestinal permeability tests are
based on the quantitation in the urine of marker molecules ingested orally. However,
not only the permeability of the intestinal surface but many other  factors such as
gastric emptying, dilution by secretions and renal clearance determine the  excretion
of marker molecules. Using two markers that differ in permeability but are affected
equally by all the other factors can eliminate these factors. This principle is called
differential permeability testing. The excretion ratio of these two markers has shown
to be a reliable test for intestinal permeability. This method of measuring intestinal
permeability is widely accepted and used for testing mucosal dysfunction, making
more invasive diagnostic procedures unnecessary [3].
In this study we evaluated the  subclinical involvement  of the  gastrointestinal
tract in renal transplant recipients with CMV infection by determining intestinal
permeability with lactulose and mannitol as markers.Chapter 3 42
3.2 MATERIALS AND METHODS
One hundred eleven patients transplanted between 1990 and 1993 were included in
the study. Sixty-five were men. The mean age was 44 years (range: 18-68  years).
The  median  dialysis  period  pretransplantation  was  32  months  (range:  0-144
months).  There  were  101  first  transplantations,  9  second  and  1  third.  Six
transplantations  were  living  related.  Fifty-three  percent  of  the  patients  were
seropositive for CMV before transplantation. Patients were considered seropositive
when IgG antibodies against CMV late antigen (CMV LA) were present.  No CMV
prophylaxis (acyclovir, ganciclovir or anti-CMV immunoglobulins) was given. Initial
immunosuppression consisted of cyclosporine A and low-dose prednisolone. Patients
with a second or third transplant received  induction  therapy  with  monoclonal
antibodies (OKT3), followed by triple therapy (azathioprine, cyclosporine A and low
dose prednisolone). All patients gave informed consent before participating  in the
study.
A differential permeability test was performed  to  measure intestinal  perme-
ability. We used lactulose (342 Da, 0.52  nm) and mannitol  (182  Da, 0.40  nm) as
markers.
After an overnight fast of at least 6h and with an empty urine bladder, patients
drank 100 ml of water containing 10 g lactulose and 0,5 g mannitol. The osmolality
of the solution was 255 mosmol/l. No oral intake was allowed during the first 2h after
ingestion of the test solution, and subsequently milk or sugars were not allowed until
five hours after commencing the  test.  Urine was collected during a period of five
hours after the test solution had been ingested. The volume of the urine collected was
recorded and an aliquot was refrigerated at –20 °C until the time of analysis.
The lactulose and mannitol concentrations in the  urine were measured by gas
liquid chromatography as described by Laker [4] and Laker and Mount [5] respec-
tively, with minor modifications. Briefly,  the  samples were mixed with internal
standard  solution  (a-methyl  glucose),  washed,  and  dried.  Pyridine/hydroxysil
(Chromopack, Middelburg, The Netherlands) was added and the specimens and heated
at 60 °C for 2 h. Samples were analyzed in a Packard 428 chromatograph (Packard-
Becker, Delft, The Netherlands) on a 200-cm column of 3% OV-1 (Chromopack,
Middelburg, The Netherlands), operated at 190 °C for 7 min and at 250 
oC for 6 min;
the temperature was elevated from 190 °C to 250 °C in 12 min. Mannitol, 1 mmol/l,
and lactulose, 1 mmol/l, were used as standard solutions (Janssen Pharmaceutica,
Belgium).
The lactulose mannitol excretion ratio (LM ratio) was calculated by dividing the
urinary lactulose excretion by the urinary mannitol excretion expressed as percent-Increased intestinal permeability 43
ages of the ingested doses. Normal values are below 0.030  and are independent of
renal function. Especially in our patients, who had a broad range of glomerular filtra-
tion rates, it was necessary to be very sure about the independency of renal function,
as reviewed in the literature [3, 6]. For this reason we measured the LM ratio in 10
non-transplanted patients without gastrointestinal diseases from the outpatient renal
clinic and with glomerular filtration rates below 25 ml/min: these ratios were in the
normal range.
Diagnosis of active CMV infection was made using the CMV pp65-antigenemia
assay, as described by Van der Bij et al [7, 8]  and reviewed by Chou [9]  and by
Ljungman and Griffiths [10] during the Fourth International CMV Workshop (Paris,
1993). In short, peripheral blood leucocytes were isolated, cytocentrifuged and in-
cubated with a mixture of monoclonal antibodies directed against a 65-66 kD CMV
antigen, followed by immunoperoxidase staining. The  number of antigen-positive
cells per 50.000  leukocytes was counted in triplicate.  The  antigenemia assay was
performed at least once weekly starting on postoperative  day (pod) 12. In all pa-
tients the antigenemia was followed by either seroconversion (primary infection) or
significant rise (reactivation) in CMV IgG antibodies. IgM and IgG CMV antibodies
were measured quantitatively by ELISA using late stage CMV-infected fibroblasts as
antigens [11].
Intestinal  permeability  was  measured  with  the  LM  test  at  pod  10  after
transplantation to avoid the possible bias of the postoperative state.  Those  values
are referred as baseline values. During active CMV infection, diagnosed by a positive
antigenemia assay, the intestinal permeability was measured again (median day pod
40). In five patients we were able to perform more than one permeability test during
CMV infection, in the analysis we used the  result of the  test  with the  highest LM
ratio. Since we measured the LM ratios during CMV infection on median day pod 40
we also measured LM ratios on median pod 40 in a control group of renal transplant
recipients without CMV.
Statistical analysis was performed using the Wilcoxon signed rank test and the
Mann-Whitney U test. Differences in creatinine clearances were evaluated by stu-
dent’s t-test.Chapter 3 44
3.3 RESULTS
We performed 104 lactulose mannitol tests (LM) test on pod 10 (baseline values),
18 during active CMV infection and 9 on pod 40 without CMV infection. Twenty-
nine patients (29%) contracted an active CMV infection,  14 secondary infections
versus 15 primary ones. In twelve of them the intestinal permeability was tested at
least once during infection (7 secondary versus 5 primary infections). In this group
5 patients were asymptomatic and 4 had fever as the  only symptom,  while 3 had
fever as well as leukocytopenia  and thrombocytopenia.  Ten  of these 12 patients
were hospitalized. The other 17 patients with CMV infection refused to  undergo a
LM test. Of these 17 patients 15 were hospitalized. They  did not  differ clinically
from the group that was tested. In none of the 29 patients with an  active  CMV
infection was clinical gastrointestinal  symptomatology  apparent.  Compared  to
baseline values, the LM ratio increased during active CMV infection in 9 out of the
12 patients that could be studied. For these 12 patients  a significant increase (P <
0.01) was observed from a median of 0.030  (range 0.004-0.056)  to  0.060  (range
0.013-0.279; figure 3.1). In addition, the LM ratio during active CMV infection was
significantly  (P < 0.01) higher than in the control  patients  measured at  pod  40
(median  0.007,  range  0.004-0.032;  figure  3.2).  No  correlation  could be  found
between the LM ratio and clinical signs of infection, the  height of antigenemia or
humoral immune response. Control  patients  had a significantly (P < 0.05)  better
renal function than the CMV patients on pod 10 (mean creatinine clearance (CrCl)
on pod 10: 61 vs. 40 ml/min). During CMV infection there was a tendency towards
a lower CrCl in the CMV group than in the control group on pod 40 (mean CrCl 49
vs. 64ml/min) but this did not reach statistical significance. The tendency towards a
slightly higher CrCl in patients without CMV infection was most likely caused by the
more frequent rejection episodes in the CMV group. The  mean  CrCl on  pod  10
compared to pod 40 did not differ significantly in the two groups (40 vs. 49 ml/min
in the CMV group and 61 vs. 64 ml/min in the control group).Increased intestinal permeability 45Chapter 3 46
3.4 DISCUSSION
Our data appear to support involvement of the gastrointestinal tract  during active
CMV infection in renal transplant patients in absence of gastrointestinal symptoms.
This may indicate that the majority of patients  with active CMV have subclinical
enteropathy as evidenced by  an  increased permeability  of  the  intestinal  barrier.
Previous studies have shown that  about a quarter of patients  with reactivation  of
CMV after liver transplantation has evidence of CMV in their upper gastrointestinal
mucosa [12]. This study suggests that the impact of CMV infection on bowel mucosa
may be much more extensive than those previous studies showed.
The LM-test was used because it is simple and considered to be not stressful fore
patients. The  LM differential permeability test  has been shown to  provide useful
clinical information on small intestinal pathology as for example in inflammatory
bowel disease or celiac disease [3]. Nevertheless there is still confusion about the
permeation pathways of lactulose and mannitol. Lactulose  is a disaccharide that
probably diffuses between the epithelial cells of the intestinal barrier (paracellularly)
through a relatively small population of large pores formed by tight  junctions and
extrusion zones. Mannitol is a smaller molecule and diffuses between but also across
the epithelial cells (transcellularly) through a larger population of small pores. This
explains why mannitol permeation is more than 30 times higher than  that  of lac-
tulose. Intestinal disease makes the barrier leakier and less selective, thus favoring
lactulose and increasing the LM ratio.
Although intestinal participation  in CMV infection  is in accordance with the
systemic nature of this type of infection, the reason for the  increased intestinal
permeability remains speculative and requires further studies. Aside from the  cyto-
pathic effects of the virus itself on the intestinal mucosa, it has been suggested that
a more widespread infection of endothelial cells by the  CMV might play a pivotal
role in the pathofysiology of CMV infection, possibly explaining the protean symp-
tomatology of the infection [13, 14]. The virus is latent in tissue cells of the trans-
planted organ or of the recipient. The  virus may be reactivated  as a result of im-
munosuppression in the transplanted patient. According to our hypothesis, the virus
most likely spreads from cell to cell until, at some point  during this process endo-
thelial cells become infected. In the following phase mononuclear and polymorpho-
nuclear leucocytes will adhere to the infected endothelium and ingest the  virus and
the pp65 matrix protein, which has been proven to be the viral protein detected in
the CMV antigenemia test [15]. Finally, the infected endothelial cells detach and can
be seen in the blood as circulating, cytomegalic endothelial cells [13, 14]. Endothelial
damage causing microvascular obstruction or plugging of these large circulating CMV-Increased intestinal permeability 47
infected endothelial cells may damage the integrity of the intestinal epithelial cells
by  hypoxemia  and  may  explain  the  increased  intestinal  permeability  in  CMV
infection.  A  variant  on  this  hypothesis  could  be  that  the  virus  infects  the
enterocytes, causing cellular damage and loss of barrier function.
Clinical implications of the increased permeability can only be speculated. One
important implication  could be increased permeation  of antigens during CMV in-
fection or translocation of bacteria that could influence the delicate immune balance
in transplant recipients, and be the cause of opportunistic infections.  Another  im-
plication could be an altered absorption of drugs.
In conclusion, an increased intestinal permeability indicating intestinal epithelial
damage has been found in a substantial number of patients with active CMV infection
after renal transplantation. While this finding does not, in our opinion, provide any
useful, marker of CMV infection, it could provide  some  insight  into  the  patho-
fysiology of the protean manifestations of CMV infection after  transplantation.
Further studies need to be performed to clarify the pathophysiological mechanisms
and implications of this phenomenon.   Chapter 3 48
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ABSTRACT
In addition to life-threatening pneumonia, cytomegalovirus (CMV) may also cause
subclinical pulmonary dysfunction after kidney transplantation.
To investigate the role of plugging of cytomegalic endothelial cells (CEC) in the
pulmonary capillary bed we prospectively determined specific carbon monoxide dif-
fusion capacity (KCOc), and its components: the pulmonary diffusing membrane fac-
tor (Dm) and pulmonary capillary blood volume  (Vcap) before and during CMV
infection in 13 kidney transplant recipients and 13 controls.
During CMV infection mean KCOc decreased significantly by 28% of the initial
value (mean KCOc 79 vs. 109; P < 0.005) due to a decrease in both Vcap and Dm.
The KCOc in controls showed a significantly smaller decrease due to a slightly lower
Vcap.
We  conclude  that  kidney  transplant  recipients  with  CMV  infection  have
significant pulmonary diffusion disturbances due to a combination of lower Vcap and
lower Dm. The most likely explanation for this phenomenon is a local inflammatory
process due to CMV and not plugging of cytomegalic endothelial cells only.Pneumonitis and plugging 53
4.1 INTRODUCTION
Cytomegalovirus infection is the most frequent infectious complication after kidney
transplantation. Although CMV infections occur in many kidney transplant recipi-
ents, a substantial number of these infections are asymptomatic. Most patients with
a symptomatic CMV infection have a self-limiting CMV syndrome that consists of
fever with malaise and arthralgias, leucocytopenia, thrombocytopenia, and elevated
serum liver enzymes (especially transaminases). Less common is the involvement of
the lungs [1, 2],  gastrointestinal  tract  [3,  4,  5],  eyes, kidney,  heart  or  nervous
system. Clinical manifestations of CMV-related pulmonary involvement range from
mild dyspnea to severe respiratory insufficiency due to CMV-pneumonitis.
We hypothesize that subclinical organ involvement may  be common  during
CMV infection in kidney transplant recipients. This hypothesis is in accordance with
the systemic nature of this type of viral infection. In a previous study we reported
on an increased intestinal  permeability  in  patients  with CMV infection  without
gastrointestinal symptomatology [4].
Van Son et al. [1, 2] found pulmonary dysfunction during CMV infection after
kidney transplantation in symptomatic as well as asymptomatic patients. Concomit-
ant activation of complement was seen during CMV infection [6] and there was spe-
culation about the role of complement activation in pulmonary diffusion disturbances
in these patients. A similar explanation for pulmonary dysfunction was found during
hemodialysis treatment, when complement activation due to the dialysis membrane
causes leukocyte aggregation and subsequent plugging in  the  lung capillaries [7].
These findings might be attributable to a decrease in the pulmonary capillary blood
volume.
Recently, we described the presence  of  large  cytomegalic  endothelial  cells
(diameter 30-35mm) in the peripheral blood of patients with CMV infection [8]. This
prompted us to study whether plugging of these large cells in the capillary bed of the
lungs might play  a causative role  in  the  pulmonary  dysfunction  found in  these
patients.
To study this possibility we measured the  diffusion of carbon monoxide (CO)
from the alveolar space to the pulmonary capillary blood. The ability of oxygen (O2)
and CO to diffuse through the alveolar-capillary membrane is similar. Yet we chose
to use CO and not O2 since the transport of CO from alveolar gas to blood is limited
by diffusion.
Briefly, after a single breath of a gas mixture consisting of O2, helium and CO,
the CO that is taken up in the expired alveolar gas is measured. The uptake of CO is
called the ‘transfer factor’ for CO (TlCO) and represents a very sensitive method toChapter 4 54
determine pulmonary diffusion. Since the total transfer of CO is also influenced by
the alveolar volume, the specific CO diffusion capacity (TlCO divided by the alveolar
volume: KCOc) is used. The KCOc is used in routine clinical practice to indicate
pulmonary  diffusion  capacity  e.g.  to  detect  subtle  changes  during  bleomycin
chemotherapy  [9].
A drop in CO diffusion may be caused by a number of factors including a decrease
in pulmonary capillary blood volume (Vcap; as might be the case in  plugging of
cytomegalic endothelial cells into the pulmonary capillary bed), a  change in  the
barrier that exists between the alveolar space and the blood (the membrane diffusion
capacity Dm), or a decrease in both components. By measuring TlCO at high and low
O2 concentrations Dm and Vcap can be determined.
In this study we investigated the cause of disturbed CO diffusion by measuring
KCOc and its components, Dm and Vcap. To detect any relationship  between
decreased CO diffusion and changes in Dm, e.g., interstitial edema, or changes in
Vcap that are compatible with plugging of endothelial cells or leukocytes in the capil-
lary bed, or possible changes in both components  that  are compatible with pneu-
monitis, all pertinent recipient data were evaluated.
4.2 MATERIALS AND METHODS
4.2.1 Patients
Thirty-nine patients who underwent transplantation from April 1995 through March
1997 were included in this study. None of the patients had a history  of pulmonary
disease and all had normal physical examination  and chest X-ray during the  study
period. Patients with postoperative  cardiopulmonary complications  such as myo-
cardial ischemia or infarction, pulmonary embolism or bronchopneumonia were ex-
cluded from the study. Twenty-five patients were men and 14 women. Their mean
age was 43 years (range 18-66 years). The median dialysis period prior to transplant-
ation was 46 months (range 0-141 months). The study population consisted of 37
first kidney transplants, 2 retransplants and 3 living related transplants. Fifteen pa-
tients were seropositive for CMV before transplantation. Patients  were considered
seropositive when IgG antibodies against CMV late antigen (CMV LA) were present
[10]. No CMV prophylaxis (acyclovir, ganciclovir or anti-CMV immunoglobulins)
was given. Initial immunosuppression consisted of  cyclosporine  A and low dose
prednisolone. Patients with a second or third transplant (both in the control group)Pneumonitis and plugging 55
received monoclonal  antibody  induction  therapy  with OKT3  followed by triple
therapy with azathioprine or mycophenolate mofetil, cyclosporine A and low dose
prednisolone. All three living related kidney transplant recipients were in the control
group and treated with triple therapy. Rejection episodes were treated with 1 gram
of methylprednisolone (Solu-Medrol; Upjohn, Kalamazoo, MI)  intravenously  on
three consecutive days. For steroid-resistant rejection a course of ATG (Rabbit ATG,
Merieux) was administered. All patients gave informed consent before participating
in the study.
4.2.2 Pulmonary  function
Pulmonary function was determined twice in all patients between postoperative day
10 and 25. The values obtained were taken as baseline values. In one patient  only
one baseline value could be taken. In thirteen  patients  with active CMV infection
pulmonary function was measured at least twice (mean number of measurements 5;
range 2-16) during the infection. In the subsequent analysis the  results of the  pul-
monary function with the lowest specific CO diffusion were used. In the first 8 pa-
tients with active CMV infection the lowest pulmonary diffusion values were deter-
mined on median postoperative day 56. For this reason pulmonary function assess-
ment in the control group of patients without CMV was also performed on day 56.
Forced  expiratory  volume  in  1  second  (FEV1)  and  slow inspiratory  vital
capacity (VCmax) were determined by spirometry. The transfer factor  (diffusing
capacity) for CO (TlCO) and its components, i.e., diffusing capacity of the alveolar-
capillary membrane (Dm) and volume of blood in the pulmonary capillaries (Vcap)
were determined from triplicate  measurements  of  TlCO  at  high (88%)  and low
(19.2%) concentrations of inspired oxygen. The single breath technique of Krogh as
modified by Cotes [11], was used. Carbon monoxide was measured with an infrared
spectrophotometer and helium using a thermal conductivity method (ML-Masterlab-
Transfer; Jaeger Germany). The TlCO values were corrected for hemoglobin con-
centrations (TlCOc) according to Cotes [11]. Corrected, specific diffusion capacity
(KCOc) was calculated by dividing TlCOc by the alveolar volume. The Dm and the
Vcap were derived from the equation of Roughton and Forster [12]:
1/TlCO = 1/Dm + 1/q[Hb].VcapChapter 4 56
where q is the reaction rate of CO with hemoglobin (Hb) at the average normal Hb
concentration (9 mmol/l).  [Hb] is the  hemoglobin  concentration  as fraction  of
normal. Values were expressed as percentages of those predicted, with the predicted
values being taken from Cotes et al. [13], and Quanjer et al. [14].
4.2.3 Cytomegalovirus  infection
The diagnosis of active CMV infection was made using the CMV antigenemia assay,
as described by Van der Bij et al [15, 16] and reviewed by Chou [17] and by Ljungman
and Griffiths [18] during the  Fourth International  CMV Workshop  (Paris, 1993).
Briefly, peripheral blood leukocytes were isolated, cytocentrifuged and incubated with
a mixture of  monoclonal  antibodies directed against a 65-66  kD  CMV antigen,
followed by immunoperoxidase staining. The number of antigen-positive  cells per
50.000 leukocytes was counted in duplicate. The antigenemia assay was performed
at least once weekly starting at pod 12. In all patients antigenemia was followed by
either seroconversion (primary infection) or significant rise (reactivation) in CMV
IgG antibodies. IgM and IgG CMV antibodies were measured quantitatively by ELISA
using late stage CMV-infected fibroblasts as antigens [10].
4.2.4 Statistics
Statistical analysis was performed using the Student’s t-test for paired and unpaired
samples. P values < 0.05 were considered significant.
4.3 RESULTS
39 patients performed a total of 194 pulmonary  function  tests. Eighteen patients
contracted active CMV infection: 10 primary infections (donor seropositive  and
recipient seronegative: pos-neg combination), one reactivation (neg-pos) and seven
pos-pos combinations. In thirteen patients  with active CMV infection  pulmonary
function was tested at least twice during infection (10 primary infections and 3 pos-
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cause of less frequent outpatient clinic visits and short duration of low antigenemia.
Twenty-one patients without CMV infection were studied to obtain baseline values;
pulmonary function in 13 patients was also studied on day 56 (control group).
None of the 18 patients with a CMV infection had any pulmonary symptoms.
Of thirteen patients tested during CMV infection, 6 patients were asymptomatic. Six
others had at least four of the following symptoms: fever, malaise, leukocytopenia,
thrombocytopenia and elevated liver enzymes. In one patient only a small increase
in transaminases was observed. Seven patients were treated with ganciclovir intra-
venously. Eight patients had rejection periods before CMV infection and were treated
with methylprednisolone (n = 4) or with methylprednisolone and subsequent ATG (n
= 4). The median time period in between the  last ATG dose and measurement of
KCOc during CMV infection was 6.5 days (3, 6, 7 and 75 days).
During CMV infection mean KCOc decreased significantly by 28% of the initial
value (mean KCOc 79 vs. 109; P < 0.005, figure 4.1) due to a decrease in both Vcap
(mean Vcap compared to baseline 79 vs. 106; P < 0.005, figure 4.2) and Dm (mean
Dm compared to baseline 67 vs. 86; P < 0.01, figure 4.3). In controls without CMV,
the mean KCOc decreased only by 9% from baseline values (100 vs. 110; P < 0.05)
due to a slightly lower Vcap (88 vs. 100; P < 0.005) but a similar Dm (87 vs. 85; NS).
The decrease in Vcap in controls  was significantly smaller than  that  in recipients
with CMV infection (12% vs. 26%; P < 0.05). The KCOc during CMV infection was
significantly lower than that in controls on postoperative day 56 (mean KCOc 79
vs.  100;  P  <  0.01,  figure  4.4).  There  was  no  difference  in  KCOc  between
symptomatic and asymptomatic patients (mean KCOc 76 vs. 83; NS). No differences
were found in spirometry (mean VCmax 109 vs. 99, and mean FEV1 102 vs. 101),
weight (75 vs. 77 kg, NS) or renal function (creatinine clearance 55 vs. 48, p = 0.12)
before and during CMV infection. No correlation  was found between cyclosporine
levels and KCOc, Vcap or Dm.Chapter 4 58Pneumonitis and plugging 59Chapter 4 60
4.4 DISCUSSION
Respiratory insufficiency due to CMV pneumonitis is a well-known complication
with high mortality in kidney transplant  recipients. Fortunately  it does not  occur
very often. In this study we showed that all of our kidney transplant recipients with
an active CMV infection had a subclinical pneumonitis even in the absence of clinical
symptoms. Van Son  and  coworkers [1, 2] demonstrated that  kidney  transplant
recipients with CMV infection have a disturbed specific diffusion capacity for CO. In
this study we found that the disturbed pulmonary diffusion during CMV infection is
due to both, a decrease in capillary volume (Vcap) and a decrease in membrane factor
(Dm).
Fluid overload or fibrosis can not explain the  decrease in diffusion. In case of
fluid overload, one would expect a smaller Dm but a normal Vcap [19]. Also, there
were no differences in bodyweight or renal function at time of CMV infection com-
pared to controls or baseline values. The presence of fibrosis is not likely since the
changes in KCOc due to CMV infection are reversible [1, 2].
It has been suggested that cyclosporine is responsible for  a decrease in  pul-
monary diffusion. In heart transplant recipients in particular, a correlation has been
found between cyclosporine levels and pulmonary diffusion. This correlation could
not be related to Vcap and, as a consequence, was related to a decrease in Dm [20].
Other authors have not found a relationship between cyclosporine  and pulmonary
diffusion  in  kidney  transplant  recipients  [21].  In  our  patient  population,  a
correlation between cyclosporine levels and pulmonary diffusion capacity could not
be detected. In the control group we found a small decrease in Vcap that contradicts
the normal Vcap in heart transplant patients with cyclosporine [20].
It has been suggested that a more widespread infection of endothelial cells by CMV
might  play  a  pivotal  role  in  the  pathofysiology  of  CMV  infection,  possibly
explaining  the  protean  symptomatology  of  the  infection  [22,  8].  The  virus  is
latently present in cells of the  transplanted  donor organ or of the  recipient.  The
virus may be reactivated due to immunosuppression and/or by cytokines such as i.e.
TNF-a induced by infection (septicemia), rejection and drugs like OKT3. Cell-to-cell
spread of the virus happens until, at some point during this process, endothelial cells
become infected. In the next phase mononuclear and polymorphonuclear leukocytes
adhere to the infected  endothelium  and take  up the  virus and the  pp65  matrix
protein, which has been proven to be the  viral protein  detected in the  CMV anti-
genemia test [23]. Finally, the infected endothelial cells detach and can be found in
the peripheral blood as cytomegalic endothelial cells [22, 8]. Plugging of these cyto-
megalic endothelial cells may obstruct the pulmonary capillaries since these infectedPneumonitis and plugging 61
endothelial cells can be as large as 35 mm and probably cannot (at least theoretically)
pass through the pulmonary capillaries (diameter 5 mm). Plugging alone, however, is
not an explanation for the decrease in diffusion, as it should only affect Vcap. Some
of the smaller cytomegalic endothelial cells most likely pass through the pulmonary
capillaries.
Another possibility is complement activation. Complement activation has been
demonstrated in the presence of active CMV infection  [6]. In dialysis hypoxemia
complement activation causes aggregation of leukocytes, which obstruct pulmonary
capillaries [7]. A similar process could take place during CMV infection.  This pro-
cess, however, should also only affect Vcap.
Although pulmonary involvement in CMV infection is in accordance with the
systemic nature of this type of infection, the cause for the decrease in Vcap and Dm
remains unknown. We speculate that a local  inflammatory  process due to  CMV
causes interstitial edema and capillary obstructi on. This subclinical pneumonitis would
explain both the decrease in Dm and Vcap. Mere plugging of cytomegalic endothelial
cells or leukocytes does not explain the disturbed pulmonary diffusion, but the
cytomegalic endothelial cells may contribute to the decrease  in  KCOc  by,  for
example, spreading of infection in the lungs. Cytomegalic endothelial cells contain
active replicating CMV [22, 8], which makes spreading of the virus in the pulmonary
capillary bed possible. This may  lead  to  a  locally  CMV-induced inflammatory
response that gives rise to local cytokine production. Cytokines such as IL-1, IL- 6,
RANTES and TNF-a have been implicated in the pathogenesis of pneumonitis (both
pro-inflammatory  as  well  as  inflammatory  effects  of  cytokines  have  been
mentioned) in experimental pneumonia [24, 25, 26],  pulmonary  toxicity  during
bleomycin therapy [27] as well as in CMV pneumonitis  after  lung transplantation
[28, 29, 30]. In the latter category of patients local cytokine production was found
in material obtained by bronchoalveolar lavage (BAL). Invasive procedures like BAL
are mandatory and justified in patients after lung transplantation  since pulmonary
symptoms might either be due to an infectious complication such as CMV pneu-
monitis or to rejection. Since none of our renal transplant recipients had pulmonary
symptoms, invasive procedures like BAL did not seem justified. Since we did not
perform BAL, we have no data concerning cytokines produced locally during CMV
infection. However, locally produced cytokines during CMV infection (caused by
cytomegalic endothelial cells transported  to  the  lungs) may, indeed, have been at
least partially responsible, via edema formation, for the decreased Dm found in our
patients.
Finally, during rejection or after ATG, cytokines are produced that  may cause
pneumonitis. Yet, the time between rejection and KCOc measurement (mean  42Chapter 4 62
days, range 7-81 days) and the time between ATG and KCOc measurement (median
6.5 days) makes the influence of rejection or ATG on KCOc less likely.
Subclinical pneumonitis in the transplant recipients with CMV was not followed
by clinical pneumonitis. This could be explained by careful CMV monitoring in these
patients, early tapering of immunosuppressive therapy during active CMV infection
and the use of  antiviral  medication  in  CMV-infected patients  during polyclonal
(ATG) antirejection therapy. In patients with CMV infection, pulmonary infections
with opportunistic pathogens such as Pneumocystis carinii, fungi, or yeast are often
seen.  Many  of  these  opportunistic  infections  are  provoked  by  the  immuno-
suppressive state caused by the antirejection  regimen as well as by the  CMV virus
itself [31]. Another reason for these opportunistic infections may be that lungs are
more susceptible for infections due to, even subclinical CMV pneumonitis.
In conclusion, all of our renal transplant recipients with CMV infection  had a
decrease in lung diffusion due to both, a lower capillary volume and a lower mem-
brane factor. A local inflammatory process due to CMV would therefore appear to
be the most likely explanation  for this phenomenon.  We believe that  this might
render the lungs more susceptible to other opportunistic infections.Pneumonitis and plugging 63
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ABSTRACT
In addition to life-threatening pneumonia, cytomegalovirus (CMV) may also cause
subclinical pulmonary dysfunction after kidney transplantation. To investigate the
role of plugging of cytomegalic endothelial cells (CEC) in the pulmonary  capillary
bed  we  prospectively  determined  specific  carbon  monoxide  diffusion  capacity
(KCOc), and its components: the pulmonary diffusing membrane factor  (Dm) and
pulmonary capillary blood volume (Vcap) before and during CMV infection  in 13
kidney transplant recipients and 13 controls.
During CMV infection median KCOc decreased significantly due to a decrease in
both Vcap and Dm. We illustrate the course of pulmonary diffusion in a male kidney
transplant recipient with CMV infection.
We conclude that kidney transplant recipients with CMV infection have signi-
ficant pulmonary diffusion disturbances due to a combination of lower Vcap and
lower Dm. The most likely explanation for this phenomenon is a local inflammatory
process due to CMV and not plugging of cytomegalic endothelial cells.Pneumonitis: a case story 69
5.1 INTRODUCTION
Cytomegalovirus (CMV) infection is a frequent infectious complication after kidney
transplantation. Despite the  fact that  in many kidney transplant  recipients CMV
infections occur a substantial part of these is asymptomatic. Most patients in whom
a CMV infection causes symptoms have a self-limiting CMV syndrome that consists
of  fever  with  malaise  and  arthralgias,  leucocytopenia,  thrombocytopenia,  and
elevated serum liver enzymes (especially transaminases).
Pulmonary symptoms are  less common;  clinical manifestations  of  CMV-related
pulmonary involvement range from mild dyspnea to severe respiratory insufficiency
due to CMV pneumonitis. Subclinical pulmonary involvement has been found in al-
most all kidney transplant patients with CMV infection by measuring specific carbon
monoxide diffusion capacity [1]. The reason for the fall  in  pulmonary  diffusion
during CMV infection remains speculative. Recently large CMV-infected endothelial
cells (diameter 30-35 mm) in the peripheral blood of patients with an
This photo shows a cytospot of the mononuclear
cell fraction (counterstained for DNA) from a
kidney transplant recipient with cytomegalovirus
infection. The large bright cytomegalic endothelial
cell (CEC) in the center is positive for both CMV-
and endothelial specific monoclonal antibodies.
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active CMV infection were described (figure 5.1)  [2,  3].  Plugging of  these  large
cytomegalic  endothelial  cells  in  the  pulmonary  capillary  bed  could  decrease
pulmonary capillary volume and this could probably explain the fall in CO diffusion
(figure 5.2).
To investigate the role of plugging cytomegalic endothelial cells (CEC) in the patho-
genesis of disturbed pulmonary diffusion during CMV infection  we prospectively
determined specific carbon monoxide diffusion capacity (KCOc) and its components:
the pulmonary diffusing membrane factor (Dm) and pulmonary capillary blood
volume (Vcap) before and during CMV infection in kidney transplant patients and in
a control group. We demonstrate the course of pulmonary diffusion parameters  in
a male kidney transplant recipient with CMV infection (figure 5.3).Pneumonitis: a case story 71
5.2 METHODS
In 13 kidney transplant recipients with active CMV infection  pulmonary  function
was measured before (median postoperative day 19) and during the infection (median
postoperative day 56). None of these patients had a history  of pulmonary  disease
and all had normal physical examination and chest X-ray. Initial immunosuppression
consisted of cyclosporine  and low-dose prednisolone.  No  CMV prophylaxis  was
given. The transfer factor (diffusing capacity, for Hb corrected) for carbon monoxide
(TlCOc) and its components (figure 5.2), diffusing capacity of the alveolar-capillary
membrane (Dm) and volume of  blood in  the  pulmonary  capillaries (Vcap) were
determined from triplicate measurements of TlCO at high (88%) and low (19.2%)
concentrations of inspired oxygen. The single breath technique of Krogh as modified
by Ogilvie and Cotes was used [4]. Carbon monoxide was measured with an infrared
spectrophotometer and helium with a thermal conductivity method (ML-Masterlab-
Transfer; Jaeger, Germany). The specific diffusion capacity (KCOc) was calculated
by dividing TlCOc by the alveolar volume [4]. The Dm and the Vcap were derived
from the equation of Roughton and Forster [5]. Values were expressed as percentageChapter 5 72
of those predicted, with the predicted values being taken from Quanjer and Cotes [6,
7]. Diagnosis of active CMV infection was confirmed using the  CMV antigenemia
assay, as described by Van der Bij et al. [8, 9]
 and reviewed by Chou [10] and by
Ljungman and Griffiths [11].
5.3 RESULTS
During CMV infection in thirteen kidney transplant recipients median KCOc de-
creased significantly by 26% of the initial value (median KCOc 78 vs. 106;  P <
0.005) due to a decrease in both Vcap (median Vcap compared to baseline 80 vs. 104;
P < 0.005) and Dm (median Dm compared to baseline 68 vs. 95;  P < 0.01).  In
controls without CMV median KCOc on postoperative day 56 decreased only by 12
% from baseline values (91 vs. 104; P < 0.05) due to a slightly lower Vcap (88 vs. 95;
P < 0.005) but a similar Dm (87 vs. 83; NS). The  decrease in KCOc and Vcap in
controls was significantly  smaller than in recipients with CMV infection. None of the
patients had pulmonary symptoms, six patients were asymptomatic, six patients had
four  out  of  five  of  the  following  symptoms:  fever,  malaise,  leukocytopenia,
thrombocytopenia and elevated liver enzymes, one patient had only elevated trans-
aminases. Eight patients  received antirejection  treatment:  four  with pulse pred-
nisolone followed by ATG and four with only pulse prednisolone. In Figure 5.3 the
course of KCOc, Vcap and Dm in a 48-year-old male kidney transplant recipient is
illustrated. This patient was transplanted May 10, 1996 after two years of dialysis.
Before transplantation he had been CMV-seronegative and he was transplanted with
a kidney from a seropositive  donor. His immunosuppressive regimen consisted of
cyclosporin and low dose prednisolone. He had no rejection episodes before or during
CMV infection. During the CMV infection he developed no pulmonary  symptoms
and had a normal chest X-ray. He was treated with ganciclovir.
5.4 DISCUSSION
We conclude that kidney transplant recipients with CMV infection have a disturbed
specific diffusion capacity for carbon monoxide caused by both, a decrease in capil-
lary volume as well as a decrease in membrane factor. The course of KCOc, Vcap and
Dm is demonstrated in a male transplant patient with CMV infection. CMV infectedPneumonitis: a case story 73
cytomegalic  endothelial  cells  (CEC,  diameter  35  mm) [2, 3] cannot, at  least
theoretically, pass the pulmonary capillaries (diameter 5  mm). Plugging of  these
cytomegalic endothelial cells alone, however, is not an explanation for the decrease
in diffusion as this should only affect Vcap and not Dm. We speculate that  a local
inflammatory process due to CMV causes interstitial edema and capillary obstruction.
This would explain the decrease in both capillary volume and membrane factor.  The
CECs containing active replicating CMV [2, 3] might contribute to the decrease in
KCOc by spreading infection in the lungs. This may then lead to a locally  CMV
induced  inflammatory  response.  The  difference  between  subclinical  and  overt
pneumonitis is probably only quantitative. Determination of subclinical pneumonitis,
however, allows us to recognize important pathophysiological clues. Also, subclinical
pneumonitis could render the lungs more susceptible to opportunistic infections.Chapter 5 74
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ABSTRACT
The  pathophysiology  of  CMV  infection  may  involve  many  different  organs
including the lungs. In this study we investigated  CMV antigenemia  levels  and
cytomegalic endothelial cells (CEC) in blood in relation to the pulmonary diffusion
capacity.
Patients with high  CMV antigenemia  (≥ 100  pp65
+ PMNs/50.000)  (n  = 8)
showed a more extensive decrease in the membrane factor (Dm) than patients with
lower levels of CMV antigenemia (n = 7). The decline of the  diffusion capacity  of
the alveolar capillary membrane (KCOc) and of the pulmonary capillary volume
(Vcap) was the same in both groups. Four out of nine patients had CEC in the range
of 0.22 CEC/ml to 30.26 CEC/ml. All the CMV patients showed a decreased KCOc
together with a decrease of Dm and Vcap but no difference was observed between
patients with and without CEC. We conclude that  a higher viral load is associated
with a more extensive  decrease in the  membrane factor  and therefore  with more
subclinical pneumonitis. No  relation  was observed between CEC and pulmonary
dysfunction. Therefore, we  postulate that  CEC  levels  are  related  indirectly  to
subclinical pneumonitis mediated via the viral load.Pneumonitis and antigenemia 79
6.1 INTRODUCTION
Although cytomegalovirus (CMV) infection is one of the most frequent infectious
complications after organ transplantation, the  pathophysiology  of  CMV disease
remains speculative. Introduction of the cytomegalovirus pp65  antigenemia assay
enabled early and rapid diagnosis of CMV-viremia prior to symptoms in transplant
patients [1].  After kidney transplantation,  cytomegalovirus infection  most often
causes a flu-like syndrome with fever, arthralgia, leukocytopenia, thrombocytopenia
and elevated liver enzymes in symptomatic patients. The number of pp65 positive
polymorphonuclear cells per 50.000 leukocytes is related to clinically symptomatic
CMV disease [2]. The majority of patients with positive CMV antigenemia remain
asymptomatic  because  of  preemptive  treatment  with  ganciclovir  in  case  of
institution of antirejection therapy. However, those still asymptomatic patients may
have subclinical manifestations of CMV. We demonstrated, for example, increased
intestinal mucosal permeability for disaccharides like lactulose in kidney transplant
recipients with CMV infection  [3]. Cytomegalovirus causes subclinical pulmonary
dysfunction  in  kidney  transplant  recipients  with  or  without  CMV-associated
symptoms [4, 5]. Whether the disturbed pulmonary diffusion or damage of intestinal
integrity precede or coincidence with clinical pneumonitis or colitis is unknown. An
important pathophysiological role was suggested for cytomegalic endothelial cells
(CECs). CECs can be detected in peripheral blood in half of the  patients  with high
pp65-antigenemia levels [5] and are related to high antigenemia levels [7, 8].
In a previous study [4] we found a decrease in pulmonary diffusion during CMV
infection due  to  a combination  of  a lower membrane  factor  (Dm)  and a lower
pulmonary capillary volume (Vcap). We concluded that a local inflammatory process
is the most likely explanation for the decrease in pulmonary diffusion as opposed to
plugging of circulating cytomegalic endothelial cells (diameter 35-45 mm) in the pul-
monary capillaries. In our opinion endothelitis and dissemination of the virus by cir-
culating cytomegalic endothelial cells is important in the pathophysiology of CMV
disease. In a recent study we demonstrate that the incidence of CEC was associated
with CMV-related clinical symptoms [6]. In this study we investigated the  relation
between antigenemia levels, CEC in blood and the decline in pulmonary diffusion in
15 kidney transplant patients.Chapter 6 80
6.2 PATIENTS AND METHODS
Fifteen kidney transplant patients who developed CMV infection  were included in
this study. All patients had received a cadaveric transplant. None of the patients had
a history of pulmonary disease and all had a normal physical examination and chest
X-ray during the study period. Patients with postoperative cardiopulmonary compli-
cations, such as myocardial ischemia or infarction, pulmonary embolism, or broncho-
pneumonia, were excluded from the study. Initial immunosuppression consisted of
cyclosporin A and low dose prednisolone. One patient received an induction course
of OKT3. All patients gave their informed consent before participating in the study.
Pulmonary function was determined in all patients  at approximately  15 days
after transplantation (baseline value) and at least twice during CMV infection (medi-
an number of measurements 5, range 2 - 15). The transfer factor (diffusion capacity)
for CO (TlCO) and its components, the diffusion capacity of the alveolar-capillary
membrane (Dm) and the volume of blood in the pulmonary capillaries (Vcap), were
determined from triplicate measurements of TlCOc at high (88%) and low (19,2%)
concentrations of inspired oxygen. The single breath technique of Krogh, as modified
by  Cotes  was  used  [9].  Carbon  monoxide  was  measured  with  an  infrared
spectrophotometer and helium using a thermal conductivity  method  (ML-Master-
lab-transfer; Jaeger, Germany). The TlCO values were corrected  for  hemoglobin
concentrations (TlCOc), according to Cotes [9]. Corrected, specific diffusion capac-
ity (KCOc) was calculated by dividing TlCOc by the alveolar volume. The Dm and
the Vcap were derived from the equation of Roughton and Forster [10]:
1/TlCO = 1/Dm + 1/q[Hb].Vcap
In this reaction, q is the reaction rate of CO with hemoglobin (Hb) at the  average
normal Hb concentration (9 mmol/l). [Hb] is the hemoglobin concentration as a
fraction of the average normal Hb concentration. Values are expressed as percentages
of those predicted, the predicted  values being taken  from  Cotes  et  al. [11]  and
Quanjer et al. [12].
Patients were monitored for CMV pp65-antigenemia twice a week. This test was
performed according the procedure recently reviewed for standardization [1].
No CMV prophylaxis such as ganciclovir, acyclovir or hyperimmune  gamma-
globulin was given. Eight patients received ganciclovir because of clinical symptoms
associated with rising CMV antigenemia values or preemptive because of antirejec-
tion treatment. CEC in blood was studied at approximately 15 days after transplanta-Pneumonitis and antigenemia 81
tion (i.e. before infection)  and weekly during CMV infection.  This was continued
until the CMV antigenemia was negative (n = 4) or less than 5/50.000 cells (n = 5).   
CEC in blood  were analyzed  as  has  been  described recently  [6].  In  brief,
mononuclear cells (MNC) were isolated by density centrifugation using Lymfoprep
(Nycomed Pharma AS, Oslo, Norway). 1 x 10
5 MNC were cytocentrifuged on a slide.
The cytospots were stained by indirect immunofluorescence with the following
antibodies: C10/C11 directed against CMV pp65 and E1/1 2.3 directed to a 90 kDa
cell surface antigen of endothelial cells [13].  Four cytospots  were analyzed if the
concentration of MNC/ml blood was 1.5 x 10
6 or less, otherwise 6 to  8 cytospots
were analyzed. The number of analyzed slides represented a detection  limit of 20
CEC/ml blood in 95% of all samples.
Statistical analysis was performed using Student’s t-test for paired and unpaired
samples.
6.3 RESULTS
In this study, CO diffusion was determined in 15 patients (9 male / 6 female) with
active CMV infection. The median age was 42 years (range 18 - 63 years). Eleven
patients had a primary infection (positive donor organ, negative recipient) and theChapter 6 82
remaining four patients had secondary infections (positive - positive combination).
Nine patients had clinical symptoms such as fever, malaise, leukocytopenia, throm-
bocytopenia and elevated liver enzymes. Nine out of the fifteen patients were studied
for CECs (table 6.1). CECs were observed in four out of these nine patients. In two
patients CECs were observed once; in one patient twice, and in the last patient even
six times during the course of CMV antigenemia. The CECs concentrations  ranged
from 0.22 CEC/ml to 30.26 CEC/ml (median 1.28 CEC/ml).
The decrease in KCOc observed during CMV infection was similar for patients with
and without CECs (22.28 ± 22.0 versus 23.0 ± 25.0, P = ns). The decrease in Vcap
and Dm was also similar (17.03  +/-18.9 versus 19.94  ± 18.0,  P = ns and 28.7 ±
23.85  versus  17.56  ±  3.8,  P  =  ns,  respectively)  (table  6.1a).
The CO diffusion was analyzed in relation to the severity of infection. Patients
with high CMV antigenemia (≥ 100 pp65
+ PMNs/50.000) showed a more extensive
decrease of Dm than patients with low or moderate CMV  levels  (<100  pp65
+
PMNs/50.000) (29.48 ± 20.33 versus 6.69 ± 12.26,  P < 0.05).  These differences
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P = ns and 21.01 ± 11.89 versus 31.67 ± 21.25, P = ns, respectively) (Table 6.1b).
Patients with and without CMV associated clinical symptoms did  not  differ  in
decreases of KCOc, Vcap and Dm (KCOc: 25.57 ± 9.91 versus 25.0 ± 5.36, P = ns;
Vcap: 28.34 ± 22.08 versus 22.45 ± 4.40, P = ns; Dm 17.99 ± 21.4 versus 20.12 ±
20.27, P = ns).
In figure 6.1 the course of KCOc, Vcap and Dm in a kidney transplant  patient
with CMV infection is illustrated. CEC were studied weekly and appeared four days
after the maximal CMV antigenemia value. At that  time the  Dm and KCOc were
decreased (32% and 8%) while the Vcap showed an increase of 22%.
6.4 DISCUSSION
During CMV infection, patients had a decreased pulmonary diffusion capacity  that
affected both Vcap and Dm. The  balance between disturbances of  the  individual
components was influenced by the severity of the infection, but we did not observe
a specific influence of CEC in blood on either the Vcap or the Dm.
To clarify the contribution of CEC in blood, nine patients were studied for the
occurrence of CEC. No evident differences in pulmonary diffusion capacity were
observed between patients with and without CEC. Although the numbers were small,
no tendency  towards a diminished Vcap was observed. The  numbers of  CEC in
patients varied between 0.22  CEC/ml to  30.26  CEC/ml, equivalent to  1.100  to
151.300 cytomegalic cells per 5 l of blood at that moment. Apparently, these num-
bers are too low to cause a measurable obstruction of the blood flow in the lungs, in
addition to the decrease already observed in all CMV patients. Alternatively, the
CECs might either be disrupted in the capillaries or be deformed and circulate normal-
ly, like genuine blood cells.
Because CECs are strongly related to high CMV antigenemia levels, we analyzed
the severity of infection, as indicated by CMV antigenemia levels, in relation to CO
diffusion as well. Patients were divided into groups with high CMV antigenemia levels
(≥ 100 pp65
+ PMNs/50.000) and moderate to low antigenemia levels (< 100 pp65
+
PMNs/50.000). In the high CMV antigenemia group, the Dm decreased more than
in the group with low CMV antigenemia, representing increased diffusion resistance
from the alveolus to the capillaries. An inflammatory reaction with production of
cytokines, fluid extravasation and cellular infiltrate could underlie these findings. The
infiltrating cells can be composed of T cells, monocytes  and macrophages  [14].
Monocytes and macrophages are capable to produce nitric oxide (NO). NO has besideChapter 6 84
immunomodulatory  properties,  strong  vasoregulatory  effects  [15],  which  may
(partially) compensate the decrease in Vcap.   
In conclusion we found a significant decrease in Dm during more severe CMV
infection. This indicates that  the  severity of subclinical pneumonitis  is related to
maximal antigenemia levels. We have not proven a relation between CECs and the
decrease in Dm and Vcap. In the past, high viral loads expressed by high maximum
antigenemia levels were related to CEC levels. We think that CEC levels are indirect-
ly related to more extensive  decreases in pulmonary  diffusion, but because of low
numbers of patients this could not be demonstrated.Pneumonitis and antigenemia 85
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ABSTRACT
Although Cytomegalovirus (CMV) pulmonary involvement after solid organ trans-
plantation is infrequently seen nowadays, CMV pneumonitis is still a potential lethal
complication, especially in bone marrow transplant recipients. However, subclinical
manifestation of pulmonary involvement is a frequent phenomenon. In this review
we discuss pulmonary involvement of CMV infection in the  immunocompromised
host with the emphasis on transplant recipients. The clinical course, diagnosis, thera-
py, prophylaxis and pathofysiology of CMV pneumonitis are discussed.   CMV pulmonary involvement 89
7.1 INTRODUCTION
Cytomegalovirus (CMV) infection is a frequent complication after organ transplanta-
tion. Nowadays CMV infection occurs in more than  50% of all kidney transplant
recipients, but a substantial number of these infections are asymptomatic. Asympto-
matic cytomegalovirus infections can become chronic and smolder like a subsoil fire
in a peat bog. In this manner CMV could play a role in the development of chronic
transplant dysfunction and atherosclerosis [1, 2, 3, 4]. Symptomatic patients usually
have a self-limiting CMV syndrome consisting of fever, malaise, arthralgias, leuko-
cytopenia, thrombocytopenia and elevated transaminases. Clinical involvement of
the lungs [5, 6], gastrointestinal tract [7, 8, 9], eyes, kidney, heart or nervous system
is seen less frequently.
In this review we will focus on pulmonary involvement during cytomegalovirus
infection in immunosuppressed patients with emphasis on transplant recipients.
7.2 DIAGNOSIS OF CMV PNEUMONITIS
Clinical manifestations of CMV pneumonitis range from mild dyspnea to  severe
respiratory insufficiency. Diagnosis of CMV pneumonitis is usually based on symp-
toms of fever, dyspnea and diffuse infiltrates on the chest X-ray in combination with
CMV found in the broncheoalveolar lavage (BAL) by either a positive virus culture
of the fluid, or detection of cells with CMV-positive immunostaining or  cytopatho-
genic effects. The definitive diagnosis of CMV pneumonitis is made
 on transbronchial
or open lung biopsy specimens showing cytomegalic cells associated with inflam-
mation.
However, transbronchial biopsies are performed rarely because of the risk of
bleeding especially in thrombocytopenic patients,  and even  with multiple  trans-
bronchial biopsies the diagnosis may be missed. To illustrate the rather poor sensiti-
vity of transbronchial biopsies for diagnosing CMV pneumonitis the following case
history is disconcerting [10]. A fatal CMV pneumonia is described in a renal trans-
plant patient on triple immunosuppressive therapy (cyclosporin, mycophenolate
mofetil and prednisolon). CMV-PCR from alveolar cells and lung biopsy material was
repeatedly negative despite high CMV pp65 antigenemia [11]. Diagnosis was made
by open lung biopsy. A severe chronic destructive, consolidating pneumonia with
partial necrosis of lung tissue and thrombosis of smaller vessels was seen. In addition
a widespread and intense positivity of immunostaining for CMV was detected whileChapter 7 90
there was no evidence of other pathogenic agents including fungi and mycobacteria.
The thrombosis of smaller vessels found in this case is compatible with the suspected
role of endothelial damage and clotting in the pathogenesis of CMV infection [12].
In different groups of immunosuppressed  patients Tamm et al. [13] reported the
incidence of positive CMV culture found in broncheoalveolar lavage by viral culture
between 24.2-29.0% (resp. HIV, stem cell transplantation, renal transplantation and
autoimmune disease). In patients who were treated with high dose chemotherapy the
incidence  was  lower  (4.4%),  probably  due  to  the  relatively  short  duration  of
immunosuppression in comparison with organ transplant recipients. In contrast with
the incidence of positive CMV culture in BAL, clinical CMV pneumonitis was only
diagnosed in respectively 4.4, 5.8, 8.2 and 0% of the same patients. This indicates
a low predictive value of positive CMV culture for CMV pneumonitis. In this study
[13] CMV pneumonitis was better predicted by a positive immunostaining of BAL
fluid. Especially in HIV patients the discrepancy between the high frequency of CMV
in BAL culture and the low frequency of clinically overt CMV  pneumonitis  is
evident. Uberti-Foppa et al. found in 40 AIDS patients who died within 20 days after
undergoing BAL a predictive value for the diagnosis of CMV pneumonia of 61% for
positive and 100% for negative virus isolation in BAL fluid [14].
The finding of CMV-specific IgG in BAL is not a good marker for the presence
of CMV infection since the local humoral immune response in transplant  patients
with pneumonitis is not specific. The local humoral response is probably the result
of polyclonal B cell activation or facilitated transport  of IgG from serum to  lung
secretions. Local production or facilitated transport of CMV-specific IgG was found
in patients with CMV pneumonitis and in patients with pneumonitis where no CMV
was detected. Also Herpes Simplex Virus IgG can  be found in  patients  with our
without CMV pneumonitis [14].
Also CT-scan findings in cytomegalovirus pneumonia are not  specific. In 10
transplant patients (one kidney, four lung and five bone marrow) with pathologically
proven isolated pulmonary cytomegalovirus infection the  most common  patterns
were small nodules and areas of consolidation. The consolidation was most marked
in the lower lung zones [16].
In conclusion, most methods for diagnosing  CMV pneumonitis  have  a poor
positive predictive value. The false equalizing of CMV positive BAL and CMV pneu-
monitis confuses the literature concerning the incidence of CMV pneumonitis  in
immunosuppressed patients. CMV pneumonitis is a diagnosis made clinically  in
patients with pulmonary infiltrates and cytomegalovirus in BAL, in the absence of
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7.3 CMV PNEUMONIA IN DIFFERENT PATIENT GROUPS
7.3.1 Renal  transplantation
Following solid organ transplantation the incidence of CMV pneumonia depends on
the type of allograft and the immunosuppressive regimen [13, 17, 18, 19]. A relation
with the immunosuppressive regimen was recently demonstrated by Reichenberger
et al [20]. They found in 71 renal transplant recipients with pulmonary symptoms
an increase in CMV in BAL after a change of immunosuppressive regimen from
Cyclosporin-A, azathioprine and prednisolon (C) to tacrolimus, mycofenolate mofe-
til and prednisolone (T) [20]. Diagnosis of CMV was made by the  finding of cyto-
pathogenic effects in the cells harvested from BAL fluid or by culture or immuno-
staining of the cells harvested. These patients did not receive CMV-prophylaxis. Of
91 BAL procedures in these 71 patients 27% were positive for CMV. CMV was found
in 41% vs. 19% P < 0.005 compared T  vs. C treated  patients.  In one third of all
positive BAL procedures CMV was the only pathogen found, in the other procedures
also PCP, bacteria, or other viruses were found.  Nowadays in  renal  transplant
recipients CMV pneumonia is infrequent and mortality is low due to prophylactic or
preemptive treatment with ganciclovir.
7.3.2 Liver  transplantation
In 13 of 141 liver transplant recipients who had interstitial pulmonary infiltrate
cytomegalovirus pneumonia was diagnosed by histological evidence in lung tissue or
in broncheoalveolar lavage fluid or by culture in BAL specimens. CMV pneumonia
was diagnosed at median day 38 after transplantation. One-year mortality rate was
higher in patients with CMV-pneumonia (84.6 vs. 17.2% P = 0.0001).  Death oc-
curred at a median of 17 days after the diagnosis of CMV pneumonia [21].Chapter 7 92
7.3.3 Lung  transplantation
It is difficult to investigate the pulmonary effects of CMV infection  in lung trans-
plant recipients because they are intermingled with rejection and super infection in
these patients. Pneumonitis is the most common presentation of CMV disease after
lung transplantation and its  clinical  features  can  easily  be  mistaken  for  acute
rejection. Duncan [22] showed reduced expiratory flows 6 months  after  the  trans-
plantation in lung transplant recipients with CMV infection. Lung transplant recipi-
ents with CMV infection developed more bacterial and fungal superinfections and had
a lower survival rate (70 vs. 36% 2-year survival). Ganciclovir improved patient
survival and decreased rates of superinfections.
7.3.4 Bone  marrow  or  stem  cell  transplantation
Compared with solid organ transplant recipients  CMV pneumonitis  is frequently
observed in allogenic bone marrow or stem cell transplant recipients and is associated
with a high mortality [23]. CMV interstitial  pneumonitis  after  allogenic stem cell
transplantation develops 7-10 weeks after transplantation and the mortality exceeds
70% [24].  Fascinatingly, the  incidence of  CMV pneumonitis  is higher in  MHC
disparate allogenic stem cell transplantation compared to  autologous  stem  cell
transplantation or HLA compatible allogenic transplantation [25]. Whereas the inci-
dence of CMV pneumonitis in HLA compatible donors is lower the  fatality  rate
seems to be similar [26]. These clinical observations give rise to interesting hypoth-
eses concerning pathofysiology of CMV pneumonitis and the relation  with graft
versus host disease or graft immunodeficiency after  stem cell transplantation  that
will be discussed later.
7.4 PULMONARY  DIFFUSION  DISTURBANCES:  SUBCLINICAL  CMV
PNEUMONITIS?
In addition to overt  pneumonia with pulmonary  infiltrates,  cytomegalovirus may
also cause more subtle pulmonary dysfunction. In kidney transplant recipients Van
Son et al. demonstrated pulmonary  dysfunction measured as a decreased diffusion
capacity for Carbon monoxide (KCOc) in symptomatic as well as asymptomatic kid-CMV pulmonary involvement 93
ney transplant recipients with CMV infection [5]. Concomitant activation of com-
plement during CMV infection could be demonstrated [6] and it was speculated that
activation of complement  could play  a role.  This  hypothesis  was based on  the
similarity of pulmonary dysfunction concomitant with complement  activation  by
dialysis membranes. It was stated that complement activation and sequestration of
aggregated leukocytes in lung capillary [27] could explain the dysfunction.   
Grefte et al. [28] found large cytomegalic endothelial cells in the  peripheral
blood of kidney transplant recipients with CMV infection. As an alternative explana-
tion for the pulmonary dysfunction we argued that these cells could plug in the lung
capillaries and thus affect the diffusion capacity. But additional pulmonary diffusion
studies revealed that the disturbed pulmonary diffusion during CMV infection was due
to both a decrease in capillary volume as well as a decrease in membrane factor,
pointing to interstitial pneumonitis and not capillary obstruction as the cause of the
pulmonary diffusion [29]. So the  hypothesis  that  CMV induced pulmonary  dys-
function is caused by plugging of circulating cytomegalic endothelial cells is probably
not  correct.
Other authors demonstrated that  99mTc-DTPA clearances, a different method
for measuring pulmonary diffusion, changed significantly during CMV infection on
days 45 and 60 after renal transplantation. This also confirms decreased pulmonary
diffusion capacity during CMV infection [30].
 In AIDS patients it was demonstrated that a decline in TLCO couldn’t be used
as an early marker to predict CMV lung disease in asymptomatic persons [31].
7.5 THERAPY AND PROPHYLAXIS
The incidence of CMV pneumonitis has been diminished due to the use of successful
strategies to prevent or treat severe CMV infection in the first months after organ
transplantation.
Using only seronegative donors and seronegative or leukocyte free blood prod-
ucts in seronegative recipients would be the easiest way to CMV prevention,  but
shortage of donors will not allow this strategy. Other problems of matching for CMV
are that HLA matching probably will be worse and waiting times will be longer for
seronegative  recipients.  The  question  how  graft  survival  is  affected  by  CMV
matching has not been answered yet [32].
Ganciclovir and foscavir are the two antivirals used against CMV. Ganciclovir
has to be phosphorylated by kinases of the virus [33] and subsequently the triphos-Chapter 7 94
phate of the drug inhibits the viral DNA polymerase. Foscavir inhibits viral replica-
tion by noncompetitively blocking the pyrophosphate binding site of viral DNA
polymerase, preventing cleavage of pyrophosphate from deoxynucleoside triphos-
phate and elongation of the viral DNA chain. Unlike ganciclovir, foscavir does not
require viral thymidine kinase for activation. These drugs must be administered intra-
venously. The oral Ganciclovir formula only supplies low blood levels. Valganciclo-
vir, which has a far better absorption, will be available soon for clinical practice  in
The Netherlands.   
Antibody titers are useful in assessing the risk of CMV infection at the time of
transplantation, by determination whether the donor and recipient were previously
infected with CMV. This risk stratification allows for the selective use of antiviral
therapy to prevent CMV [34, 35]. Selective prophylactic treatment of high-risk
patients avoids unnecessary adverse reactions and the development  of  resistance
[36]. In our kidney transplant unit no prophylactic therapy is used. Patients  are
monitored twice weekly with the pp65 CMV antigenemia assay. When the assay
becomes positive the patients are treated with ganciclovir before they develop
symptoms. This ‘preemptive’ strategy aims at eliminating CMV infection prior to
its manifestation as active disease. The advantage of preemptive therapy is to target
patients with CMV infection at risk for CMV disease and eliminate unnecessary toxic
treatment. The disadvantage of preemptive therapy could be that it does not  prevent
the suspected pro-inflammatory effects of the  viral infection.  The  antiviral  drugs
inhibit viral DNA synthesis and the  forming of new virions but not  the  early and
immediate early effects of the virus like upregulation of  adhesion molecules and
cytokine  production,  causing  a  state  of  inflammation  [37].  Probably  the  most
important treatment of CMV infection is reduction of immunosuppression. At our
center we reduce especially the Cellcept, because we found that after the introduction
of Cellcept patients had longer periods of CMV-viremia and higher viral loads [38].
7.6 PATHOFYSIOLOGY OF CMV PNEUMONITIS: THE  ROLE  OF  THE
ENDOTHELIUM
CMV can productively infect endothelial cells causing a cytomegalic appearance of
these cells. These infected cytomegalic endothelial cells can detach from the  basal
membrane and circulate in peripheral blood [28]. Most of the circulating endothelial
cells in kidney transplant recipients originate from  the  transplanted  organ  [39].
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cells but also of lung endothelial cells can be found [40]. Interesting is the case report
of a patient with AIDS who developed pulmonary hypertension in the months before
his death. Postmortem examination showed extensive infection of endothelial cells
with  cytomegalic  appearance  and  protruding  into  the  vascular  lumina.  These
cytomegalic cells compromised the lumen of the small vessels they  lined  [41]
explaining the pulmonary hypertension.   
The upregulation of molecules like intercellular adhesion molecule (ICAM-1),
vascular adhesion molecule (VCAM-1) or Von Willebrand Factor  (VWF) on  the
surface of endothelial cells might play a role in the pathogenesis  of  CMV pneu-
monitis [42-46]. In rat extensive vascular involvement during Rat CMV infection
was found. Endothelial activation, leukocyte adhesion and activation of the clotting
system were found [47].  Infection  of endothelial cell layers with Herpes Simplex
virus type 1 (HSV-1) or Cytomegalovirus results in an increased monocyte (MC) and
polymorphonuclear (PMN) leukocyte adherence. The augmentation of MC or PMN
adherence to virus infected endothelial cells is found to be sensitive to tunicamycin
(hindering glycosylation), suggesting that both virus infections induce the expression
of glycoproteins on the endothelial cell membrane which is responsible for the MC
and PMN adhesion. This may be the first step in CMV induced endothelial damage
[48, 49].
7.7 PATHOFYSIOLOGY OF CMV PNEUMONITIS: IMMUNOPATHOLOGY
OR  CYTOPATHOLOGY?
The observation that cytomegalovirus related pneumonitis is frequent and severe in
bone marrow transplant recipients and rare and mild in HIV infected patients might
give clues for understanding the pathogenesis of CMV pneumonitis and may point  to
underlying immunopathological mechanisms. The first authors who suggested that
immunological phenomena might play an important role in the  development  of
CMV pneumonitis were Grundy and coworkers [50]. In 1987 they proposed that
interstitial pneumonitis associated with CMV infection in transplant recipients is an
immunopathologic process due to a vigorous T-cell response to a virally induced
antigen expressed on cells in the lung. Others advocate the ‘direct viral pathology’
or  ‘cytopathology  hypothesis’.  They  state  that  the  absence  of  an  adequate
protective CD8  T-cell response causes uncontrolled CMV proliferation,  cytokine
storm and CMV pneumonitis [51]. Clinical data and studies in mice give conflicting
results and will be discussed below.Chapter 7 96
Squire et al. [52] studied 58 episodes of pneumonitis  in 68 patients  with HIV
infection. In nine episodes CMV was detected as the only infectious agent in BAL
fluid. Only two episodes were severe and ventilatory support was required. In both
cases the CD4 counts were relatively high (above 0.2x10
9 /l) and HIV infection
appeared to have been acquired shortly before presentation.  They  conclude that  a
relatively well preserved immune function is needed for the  development  of CMV
pneumonitis and used this as an argument for the immunopathology hypothesis.   
This is in concert with the knowledge that AIDS-associated or idiopathic inter-
stitial pneumonitis, which is characterized by lymphocytic  infiltration  of the  lung
tissue and pulmonary dysfunction, is likely the result of an antiviral or autoimmune
response. In a murine model of retroviral associated interstitial pneumonitis CD8+
T-cell depleted mice developed interstitial pneumonitis similarly to undepleted mice.
In contrast,  depletion of CD4+ T-cells prevented  the  development  of interstitial
pneumonitis and inhibited inflammatory cytokine expression [53].
Other studies in mice show that CMV can replicate in the lungs of immuno-
competent mice with minimal or no histological evidence of disease. Induction of
pneumonitis in mice during CMV infection requires a significant change in  host
immunity like GVH disease [51] or Cyclophosphamide [52, 53]. Shanley et al. con-
clude from experiments with cyclophosphamide  in CMV infected mice that  CMV
pneumonitis must be an immunological phenomenon. In these mice they  observed
large active spleens with in BAL material activated T-cells and NK-cells. Antiviral
agents had no effect on the  pneumonitis  despite nearly total  suppression of virus
replication. Neutralizing pan T-cell antibodies slightly increased viral replication in
the lung of these mice but almost completely  inhibited the  development  of inter-
stitial pneumonitis pointing out to immunopathological mechanisms in the develop-
ment of pneumonitis. To summarize the  studies favoring  the  immunopathology
hypothesis so far, it can be concluded that viral replication in the lung is unrelated
to the development of pathological effects and that immune response is prerequisite
for the development of CMV pneumonitis.
However, other clinical  and experimental  data  give clues that  it  is not  the
immunological reaction against CMV infected cells that leads to the development of
pneumonitis, but that a deficient cellular immune response causes uncontrolled viral
replication and pneumonitis (cytopathology hypothesis). There are several clinical
arguments for this hypothesis. In broncheoalveolar lavage studies during episodes of
CMV pneumonitis a predominance of natural killer (NK) cells and CD8 cells was
found [56]. Also observations in both immunocompetent individuals and bone mar-
row transplant (BMT) patients support the protective role of CMV-specific CD8 T-
lymphocytes  [57,  58].  Waxman  et  al.  identified  9  AIDS  patients  withCMV pulmonary involvement 97
cytomegalovirus pneumonitis and low CD4 counts (29,6 (± 22) cells/mm
3). In the 5
patients treated with ganciclovir they found resolution of pulmonary symptoms and
the patients not treated died [59].
Another argument for cytopathology  is the  clinical observation  that  in renal
transplantation CMV pneumonitis is more commonly seen in primary infections
than it is seen in secondary infections, suggesting that prior strain-specific immunity
has some protective instead of a damaging effect. Also an argument for cytopathol-
ogy is that the use of ATG or high doses of steroids has been reported  to  be a risk
factor for CMV pneumonitis.
In a murine BMT model, adoptive transfer of sygeneic BM cells was associated
with massive increases in lung CD8 cells, that resulted in the resolution rather than
the exacerbation of CMV pneumonitis [58].  Obviously, the  absence of protective
CD8 lymphocytes, which causes uncontrolled CMV proliferation, is important  for
the development of this type of CMV pneumonitis.
After intranasal inoculation in immunocompetent mice, CMV can replicate in
the lungs without causing pneumonitis, however in T-cell deficient nude mice CMV
produced a progressive focal pneumonitis, also after subcutaneous inoculation [60].
In the lungs of these mice focal aggregates of intersitial  mononuclear  cells were
found. Occasionally, the  mononuclear  cells contained  viral  nucleocapsids in  the
nucleus as well as cytoplasm. Inclusion bearing cells were occasionally found in the
endothelium of the small blood vessels. Airways were consistently normal throughout
the course of infection. Although late in the course of infection  some  mice had
accumulation of acidophilic fluid in the alveoli. In these nude mice direct damage by
the viral infection is the most likely mechanism in the development of CMV pneu-
monitis [60].
In bone marrow transplant recipients graft versus host disease (GVH) seems to
play a role in the development of CMV  pneumonitis.  In  100  patients  receiving
sygeneic bone marrow from identical twins, no GVH reaction  is expected to  occur
and no cases of CMV pneumonitis were found. However in interesting experiments
in mice, Podlech et al. [58] found in MHC disparate bone marrow transplant  reci-
pients no evidence  for  the  generation  of  recipient-specific  alloreactive  donor
cytotoxic T-cells and no histological evidence for graft versus host disease. Instead
they found dramatic lung destruction by viral replication, suggesting a failure in the
generation of protective antiviral CD8 T-cells. They  propose  that  the  cause of
pneumonitis was functional graft failure, and not graft versus host  disease [58].  So
the precise role of GVHD in the development of CMV pneumonitis  has still to  be
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Cytokine release during CMV  infection  is  probably  also  important  in  the
pathogenesis of  CMV pneumonia.  Anti-CD3  antibodies induce lethal  interstitial
pneumonitis with elevated levels of tumor necrosis factor  alpha (TNF-alpha)  and
interferon gamma four weeks after intraperitoneal injection of murine cytomegalo-
virus in mice. Despite pneumonitis CMV was only detectable in the salivary glands
and not in the lungs. These authors conclude that murine CMV pneumonitis  is not
mediated by virus in the lung, but probably by cytokines  released from T  cells, of
which responsiveness has been modified by CMV infection [61]. Also the observed
correlation between cytokine secretion and incidence of active CMV infection  in
solid organ transplant recipients points out to the importance of cytokine excretion
in the pathogenesis of CMV infection [62].   
So, how to deal with the conflicting results obtained by researchers of the
‘immunopathology  adherents’ and the ‘cytopathology supporters’? Aside from the
given fact that considerable inevitable bias, such as differences in  species studied
(animal versus man, different CMV strains, different patient groups) is hindering the
final judgment who is right, the truth might prove to  be a combination  of  both
possible explanations of this enigmatic condition. Although speculative, the delicate
balance between  achieving  a  distinct  immune  response  which  is  sufficient  for
protection, and on the other hand does not cause overt immunopathology might be
pivotal whether or not a patient will develop CMV pneumonitis.
7.8 CONCLUSION
CMV pulmonary involvement after organ transplantation  is frequently seen. The
clinical course ranges from subclinical pulmonary dysfunction to serious pneumonitis.
The pathofysiology remains speculative. In our opinion endothelialitis caused by
CMV infection, upregulation of adhesion molecules, activation of the clotting system
and  cytokine  production  are  important  factors  in  the  development  of  CMV
pneumonitis. In addition the delicate balance between achieving an immune response
which is sufficient for  protection,  and on  the  other  hand does not  cause overt
immunopathology might be pivotal in the individual patient determining whether or
not an overt CMV pneumonitis will develop. Finally, pathofysiology in the individual
patient will be influenced by factors such as the type of immunosuppression, the
antiviral drugs used, as well as the type of transplant.CMV pulmonary involvement 99
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ABSTRACT
This is a case report about a renal transplant recipient with inflammatory demyelina-
ting polyneuropathy during cytomegalovirus infection. It suggests that  replication
of cytomegalovirus is accompanied by flare-ups of the polyneuropathy. We speculate
about the pathogenesis of the polyneuropathy in relation with cytomegalovirus in-
fection.Inflammatory demyelinating polyneuropathy 109
8.1 INTRODUCTION
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease with
a prevalence of approximately 1/100.000 in the general population [1]. The  patho-
genesis of the demyelination is thought to be immune mediated but the mechanism
is uncertain [2]. Antecedent infections are reported in 35% of the  patients  with
CIDP, especially cytomegalovirus (CMV) infections [3]. The CMV infection probab-
ly triggers an immune reaction against components of peripheral nerve myelin, for
instance myelin associated glycoprotein/sulfated glucuronyl paragloboside [4].
Although CMV infections occur frequently after kidney transplantation demyel-
inating polyneuropathy is very rare in organ transplant recipients. In contrast CIDP
is relatively  frequent  in  patients  with the  acquired immunodeficiency  syndrome
(AIDS) and a relationship with CMV infection is suspected [5, 6, 7]. This is the first
case  report  of  a  patient  after  renal  transplantation  with  chronic  inflammatory
demyelinating polyneuropathy reflecting recurrence of viremia,  suggesting that
active replication of CMV  may  be accompanied  by flare  ups of  the  CIDP.  We
speculate about the pathogenesis of CIDP in this patient.
8.2 CASE REPORT
A 58-year-old male patient received a renal transplant in our hospital on 3 February
1996. The cause of his renal insufficiency was chronic glomerulonephritis. In Sep-
tember 1989 peritoneal  dialysis (CAPD) had been started. Apart  from appendec-
tomy, hemorrhoidectomy and CAPD peritonitis his medical record was uneventful.
The donor was a 47-year-old male who had died of cerebral trauma in a traffic  ac-
cident. The donor was seronegative for HIV, HBV, and HCV but seropositive  for
CMV. Our patient was seronegative for CMV, HIV, HBV and HCV. The  donor was
mismatched for one HLA B and HLA DR. Crossmatches were negative.   
The kidney was transplanted in the right iliac fossa using the external iliac vein
and artery. Immunosuppressive therapy consisted  of  cyclosporine  (Sandimmune,
Novartis, Switzerland) and low-dose prednisolone. No CMV prophylaxis was given.
Postoperatively there was immediately a  good diuresis and the  serum creatinine
decreased to 154 mmol/l on the 7th postoperative day. From postoperative day 8 the
serum creatinine started to rise as result of interstitial rejection graded Banff 1 [8].
Rejection was treated with 5 x 1g methylprednisolone (Solumedrol, Kalamazoo, MI)
intravenously (i.v.) and because of unresponsiveness followed by 3 x  antithymocyteChapter 8 110
globulin 4 mg/kg (Rabbit ATG, Merieux, France) on days 20,23 and 26. Maximum
serum creatinine was 565 mmol/l and decreased to 174.  ATG was given only three
times because of persistent thrombocytopenia (nadir 42 10
6/l) and leukopenia (nadir
0.5 10
9/l granulocytes) as well as a positive cytomegalovirus pp65-antigenemia assay
[10, 11] indicating a primary CMV infection. The  only symptom  the  patient  had
that time was a slightly elevated body temperature of 38.5 C. As soon as  the
diagnosis of primary CMV infection was made i.v.  therapy  with ganciclovir was
instituted on day 27. Maximum antigenemia was 75 CMV pp65-positive cells per 50
000 polymorphonuclear cells (75/5.10
4) during ganciclovir that was continued until
day 46. After stopping ganciclovir, antigenemia increased again with a maximum of
158/5.10
4 on day 73. On day 59 the patient noticed cold numb fingertips and toes.
Later these started aching. Pain and numbness slowly progressed towards the wrists
and entire lower legs. On day 116 he noticed diminished strength in arms and legs. He
could not lift his  teacup  and  climb  the  stairs.  This  loss  of  strength  also  was
progressive. There were no disturbances in defecation or micturition. On neurological
examination a paresis of legs and arms (distal more than proximal) was found. Loss
of  strength  was  measured  with  a  hand-held  dynamometer  and  expressed  as
percentages of the predicted  values.  He  could not  walk on  his  toes  or  heels.
Hypaesthesia, hypalgesia and loss of vibration sense were found distally from knees
and wrists. Neurophysiological examination showed reduced motor nerve conduction
velocities, with absent F-waves and H-reflexes. On needle examination no denerva-
tion was found.
A diagnosis of chronic demyelinating polyneuropathy was made. Antigenemia
assay was positive indicating ongoing CMV infection. A rise of CMV IgM and later
IgG antibody showed that the patient developed an immune response against CMV
[9]. A polyclonal hypergammaglobulinemia was found. Cerebrospinal fluid (CSF)
protein level was elevated (1.3 g/l; normal < 0.5 g/l) and CMV IgG antibodies were
found in the CSF. During treatment with immunoglobulins (Central Laboratory for
Blood transfusion, Amsterdam, the Netherlands)  0.4  g/kg i.v.  during 5  days and
ganciclovir  (days  115-122)  the  patients  neurological  symptoms  improved
dramatically (figure 8.1). Antigenemia became negative. On day 154,  however he
developed a distal grade 3 and proximal grade 4 paresis of the  legs and arms again.
Hypaesthesia of hands and lower legs and loss of vibration sense became evident.
Antigenemia was again positive in low numbers of positive cells and showed  a
tendency to rise, indicating an increasing viral load. We treated him with ganciclovir
again and prednisolone 100 mg for 6 weeks and tapered it in two months to 10 mg
orally.  Ganciclovir  was  continued  orally  for  one  year.  He  slowly  improved
neurologically and antigenemia assay became negative.Inflammatory demyelinating polyneuropathy 111
8.3 DISCUSSION
This patient developed a progressive demyelinating polyneuropathy 4 weeks after
beginning of CMV infection, during a second flare up of  CMV antigenemia,  and
during the appearance of CMV-IgM antibodies. Initially there was a good response
to immunoglobulins [12] and ganciclovir, but after stopping the ganciclovir the poly-
neuropathy became worse during a smouldering CMV infection. The  patient  im-
proved with high-dose steroids and oral ganciclovir.   
The pathogenesis of the neuropathy remains speculative. In AIDS patients CMV
has been found in the nerves and there is a good response on therapy with ganciclovir
[13, 14]. In our patient the  relapse of the  neuropathy  after  stopping ganciclovir,
followed by the recurrence of the virus in the blood as well as the good response after
restarting treatment with ganciclovir, is an argument for a causal relationship  with
CMV infection. However, clinically the neuropathy was quite different from  the
ordinary CMV-induced neuropathy, which is mainly sensory and axonal.  On  the
other hand the course of CMV-IgM also parallels the neuropathic symptoms in thisChapter 8 112
patient. This might suggest, together with the considerable improvement after  the
instigation of high-dose immunoglobulin therapy, an antibody mediated autoimmune
process [15, 16]. Yuki et al. [4] found a correlation  between  the  presence  of
cytomegalovirus DNA and a myelin antibody (ant-Mag/antiSGPG) in the sera of pa-
tients with chronic polyneuropathy.
Another possible explanation is a T-cell-mediated  auto-immune response against
myelin. Structural similarity between viral T-cell epitopes and self-peptides could lead
to the induction of an autodestructive T-cell response [17]. In contradiction to this
explanation might be that we treated our patient with aggressive polyclonal anti T-
cell therapy (ATG) before the development of CIDP.
CIDP is  a  regularly observed  phenomenon  in  AIDS patients  during CMV
infection. There are several possible explanations for the differences in incidence of
CIDP in the  AIDS population  compared to  transplant  recipients. First, HIV may
destroy nerves by direct infection of the nerves by the virus. Second, although AIDS
patients are also immunosuppressed, the nature of this suppression differs consider-
ably, which might reflect differences in sequelae leading to  a possible autoimmune
process elicited by the  viral  infection.  Third,  the  duration  of  viremia  might  be
important. In the transplant population the duration of viremia is  usually short,
being confined mostly to the period of maximum immunosuppression, i.e. shortly
after initiation of anti-rejection therapy. In the majority of patients with eventually
low-dose immunosuppression after completion of the antirejection  treatment,  the
virus will remain in a latent state after  antiviral  treatment  and the  subsequent im-
mune response. In contrast, in the AIDS population, prolonged CMV viremia is the
rule, which might be a prerequisite for the development of autoimmune phenomena.
Our patient is characterized by an unusually prolonged period of CMV viremia, which
might have been a crucial factor for the development of CIDP in this particular case.
In conclusion, this report  clearly demonstrates  the  course of chronic inflam-
matory demyelinating polyneuropathy during recurrent CMV viremia and CMV IgM
immune response. A causal relationship between CMV infection and polyneuropathy
is suggested. The question whether the virus itself or the immune response is respons-
ible for the polyneuropathy remains to be resolved.Inflammatory demyelinating polyneuropathy 113
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ABSTRACT
After transplantation cytomegalovirus (CMV) infections can cause vascular damage
to both the graft and the host. To study a possible relationship between the degree of
vascular injury, clinical symptoms of CMV infection and transplant rejection, the
appearance and numbers of endothelial cells (ECs) in blood of 54 kidney transplant
recipients were investigated in a prospective clinical study. Two types of endothelial
cells were identified: cytomegalic ECs (CECs) were detected in patients with moder-
ate or high CMV antigenemia, and uninfected ECs were observed in patients with and
without CMV infection. The incidence of either CECs, ECs, or the combination of
both was associated with CMV-related clinical symptoms (P < 0.01). Remarkably,
the occurrence of rejection episodes before CMV infection was an important risk
factor for the occurrence of ECs in blood (ECs, CECs, or both) during CMV infection
(P < 0.001).CMV, rejection and endothelial cells 117
9.1 INTRODUCTION
Human cytomegalovirus (CMV) infection is one of the most common infectious
complications in kidney allograft recipients and may cause severe morbidity [1]. In
vivo, as well as in vitro, observations have shown CMV-infected endothelial cells
(ECs) that could be involved in viral dissemination [2, 3]. Infected ECs can occasion-
ally detach from the basal membrane, enter the bloodstream and be detected in the
peripheral blood of CMV patients [4, 5]. These cytomegalic cells have a diameter of
35-45 mm and contain nuclear inclusion bodies. Clumps of cytomegalic ECs (CECs)
were demonstrated [6]. The permissively infected cells may have a role in viral
dissemination or can be involved in organ damage [5]. The incidence of CECs varies
between different immunosuppressed populations [5, 7]. CECs in peripheral blood
have been found to be associated with high virus load and organ involvement [5]
although this could not be confirmed by others [4, 7].
In  this  prospective  study  of  patients  with  CMV  infection  after  renal  trans-
plantation we studied the relationship between the appearance of distinct ECs in
blood,  CMV  disease  symptoms,  and  transplantation  rejection  episodes.  Isolated
mononuclear cell fractions on cytospots were studied by immunocytologic staining
for the presence of ECs. Further investigation with markers for different stages of
CMV infection was used to examine whether, in addition to CECs, ECs in earlier
stages of infection could also detach and gain access to the peripheral blood.
9.2 PATIENTS AND METHODS
Consecutive patients after renal transplantation were prospectively studied for CMV
infection as defined by CMV antigenemia. Patients with CMV antigenemia for less
than 1 à 2 weeks were excluded (n = 12), as were patients with vascular damage not
related to CMV infection (n = 3). Rejection episodes were diagnosed according to the
Banff criteria [8]. Treatment consisted of methylprednisolone, followed by a course
of  antithymocyte  globulin  (Merieux,  Lyon,  France)  in  case  of  steroid-resistant
rejection. Vascular rejection episodes were treated with antithymocyte globulin and
plasmapheresis. Patients were monitored for CMV antigenemia twice a week. The
CMV antigenemia test was done according the procedure recently reviewed for
standardization [1].Chapter 9 118
No CMV prophylaxis, such as ganciclovir, acyclovir or hyperimmune gamma
globulin, was given. Fourteen patients received ganciclovir because of clinical symp-
toms associated with rising CMV antigenemia values. Blood samples to study the
occurrence of ECs  were  obtained  before  CMV  infection  at  about  15  days  after
transplantation and weekly after the first positive CMV antigenemia test result. This
was continued until the CMV antigenemia test was negative (n = 32) or showed less
than 5 pp65-positive granulocytes/50.000 cells (n = 12). Blood samples of patients
without CMV infection  (n = 10) were studied at about 15, 40, 50 and 60 days after
transplantation.
CECs in peripheral blood were analyzed according to a quantitative method as
described elsewhere [4, 9]. Briefly, heparinized blood samples were obtained by
venipuncture.  The  mononuclear  cell  fraction  was  isolated  by  density  gradient
centrifugation by means of Lymfoprep (Nycomed Pharma, Oslo). On each slide 1 x
10
5 mononuclear cells were cytocentrifuged. For each sample, a variable number of
cytospots was analyzed, depending on the concentration of mononuclear cells per
milliliter of blood. Four cytospots were analyzed if there were ≤  1.5 x 10
6 mono-
nuclear cells/ml of blood; otherwise 6-8 cytospots were analyzed. The number of
analyzed slides represented a detection limit of 20 CECs/ml of blood in 95% of all
samples. This standardization of blood volume was chosen to circumvent effects of
leukopenia or leukocytosis. In a previous report we showed a recovery of 45% of ECs
from blood [9]. This correction factor was included in the calculation. The following
monoclonal antibodies were used for staining of the cytospots: C10/C11 directed
against CMV pp65 and E1/1 2.3 directed to a 90-kDa cell surface antigen of ECs
[10]. ECs were stained with E13 directed against CMV immediate-early proteins
(Seralab, Sussex, UK). Fixation was with 1% paraformaldehyde, followed by indirect
immunofluorescence double-staining with fluorescein isothiocyanate or tetramethyl
rhodamine (Southern Biotechnology Associates, Birmingham, AL) for endothelial-
specific markers and CMV antigens, respectively. CECs and ECs were determined by
counting double-positive cells or fluorescein isothiocyanate-positive cells only.
Statistical analyses were done with contingency tables (c
2 test), non-parametric
Mann-Whithney test or non-parametric analysis of variance (Kruskal-Wallis) for dif-
ferences in distribution between groups, differences between 2 groups and differences
between multiple groups, respectively.CMV, rejection and endothelial cells 119
9.3 RESULTS
Fifty-four patients were included in this study (32 men, 22 women; median age 45
years; range, 18 - 71). In total, 320 samples were analyzed (median samples per
patient, 5; range, 2 - 15). Patients were stratified into four groups depending on the
highest CMV antigenemia measurement (pp65-positive granulocytes/50.000 cells):
none, low (1-10), moderate (11-100) or high (>100). Thirteen of 16 patients in the
group with high antigenemia and 5 of 12 patients with moderate antigenemia had
clinical symptoms, such as fever, malaise, leukocytopenia, thrombocytopenia and ele-
vated levels of liver enzymes. Twenty-eight patients had one or more rejection epis-
odes: 13 patients experienced interstitial rejection responding to steroid treatment, 10
patients  had  steroid-resistant  interstitial  rejection  and  5  patients  had  vascular
rejection. Episodes of vascular rejection were associated with high virus load: none
occurred in the groups with no or low antigenemia, compared with 5 in the groups
with moderate or high antigenemia. Patients with 1 or more rejection episodes were
equally distributed among groups (P = 0.41; table 9.1).Chapter 9 120
Two distinct types of ECs in peripheral blood were observed: late-stage- infected
CECs and uninfected ECs. We never observed ECs in immediate early or early stages
of CMV infection. Both CECs and ECs were detectable in blood at or just after the
maximum CMV antigenemia peak. After maximum CMV antigenemia, ECs could be
detected for a longer time than could CECs. In 3  of 10 patients without CMV
infection, ECs were demonstrated. Two of these patients had ECs at 15 days post
transplantation,  which  was  shortly  after  a  rejection  episode.  The  other  patient
experienced neither rejection nor CMV infection. Remarkably, in the patients with
CMV infection, all ECs were detected during CMV antigenemia and never before
CMV infection.
CECs were detected in 11 (25%) of 44 patients with CMV infection (figure
9.1a): 8 of 16 patients with high antigenemia and 3 of 12 patients with moderate
antigenemia (groups 3 and 4; figure 9.1a). Concentrations of CECs ranged from 0.11
to 30.26/ml (median 0.89; figure 9.1c). In 4 patients with high antigenemia, CECs
were detected at various times during CMV antigenemia.
ECs were observed in all patient categories independent of the severity of infection
(figure  9.1b).  The  concentrations  of  ECs  ranged  from  0.17  to  114.05/ml  blood
(median 2.62; figure 9.1d).
Patients with rejection episodes had ECs in blood (ECs, CECs, or both) during
CMV infection more often (66.7%) than patients without rejection (15.0%; P <
0.001). The detection of ECs was not significantly related to the type of rejection. A
tendency could be observed to higher frequencies of CECs or ECs in patients with a
more severe type of rejection (6/13 patients with steroid-sensitive interstitial rejec-
tion vs. 12/15 of patients with vascular rejection or steroid resistant interstitial rejec-
tion).
Patients with CECs had significantly more CMV-associated clinical symptoms
(81.8%) than did patients without CECs (27.3%; P < 0.01). Eleven (68.8%) of 16
CMV patients with ECs had CMV-associated symptoms, compared with 7 (25%) of
the remaining 28 patients (P < 0.01). Fourteen patients with moderate or high anti-
genemia, of whom 7 had detectable CECs, were treated with ganciclovir. Ten of 14
patients had clinical symptoms and were treated with ganciclovir.CMV, rejection and endothelial cells 121
Figure 9.1 Frequencies (A, B) and concentrations (C, D) of cytomegalic
endothelial cells (CEC; A, C) and endothelial cells (EC; B, D) in
peripheral  blood  of  patients  with  cytomegalovirus  (CMV)
infection. Frequency is the number of patients/group with cells
at any time during infection. Hatched portions of bar are patients
with  CMV  infections;  solid  portions  are  patients  with  both
preceding acute rejection episodes and CMV infection. Groups
1-4: no, low, moderate or high antigenemia, respectively.
     1              2             3              4
                         group
      1              2              3              4
                         groupChapter 9 122
9.4 DISCUSSION
This study demonstrates that the appearance of CECs, as well as of ECs is related to
CMV antigenemia levels, as well as to CMV-associated symptoms. Intriguingly,
patients with acute rejection episodes and CMV infection had considerably higher
frequencies of ECs in peripheral blood.
In our study we detected CECs only in patients with moderate or high virus load,
which was comparable to findings of Percivalle et al [5]. In that study the CEC
numbers of individual patients were higher. This finding may have been due to the
greater immunosuppression given to these heart-lung transplant recipients, resulting
in higher virus loads and, consequently, higher numbers of CECs. In contrast, bone-
marrow transplant patients may already have CECs at low levels of CMV anti-
genemia, with numbers of CECs comparable to those seen in the present study [7].
Obviously,  factors  such  as  the  type  of  transplantation,  immunosuppression, or
whether preemptive CMV treatment was given influenced not only the course of
CMV infection but also endothelial involvement.
Release of uninfected ECs has been described for several abnormalities with
vascular injury, such as sickle cell anemia [11]. These authors describe ECs in cir-
culation in healthy persons [11]. With the procedure used in our study we were not
able to detect ECs in the blood of healthy individuals (data not shown).
The occurrence of ECs in peripheral blood was closely related to active CMV infec-
tion, even though these cells are not infected. It is unknown why these cells are re-
leased. Recently, animal models demonstrated endothelial progenitor cells originating
from the bone marrow in peripheral blood. These cells were capable of homing to
vascular lesions [12]. Characteristically, these cells were positive for CD34, but also
for CD45. In our study the ECs observed during CMV infection were negative for
CD45, making it unlikely that they were bone marrow derived.
Detection of CECs, ECs or both in CMV patients was strongly related to the
occurrence of earlier rejection episodes. CECs were mainly observed in patients with
high CMV antigenemia. In addition to a specific inflammatory reaction in the graft,
acute rejection is followed by a generalized inflammatory response. Plasma levels of
different cytokines are elevated, including tumor necrosis factor-a. Binding of tumor
necrosis factor-a could stimulate the CMV immediate early promoter/enhancer region
and thus enhance the infectivity of that cell by CMV [13].
It is also possible that the ECs originate from preexisting endothelial lesions in
the transplanted graft, probably enhanced by CMV. Especially during vascular rejec-
tion, damage is directed at the endothelium. In our study 4 of 5 patients with vascular
rejection had ECs during CMV infection. According to the Banff criteria [8] onlyCMV, rejection and endothelial cells 123
arterial involvement is a criterion for vascular rejection (Banff criteria for kidney
transplants). However, the occurrence of venous involvement (venulitis) could also
contribute to detectable endothelial damage [14]. In our center we have observed that
biopsy-proven  interstitial  rejection  of  kidney  transplants  with  evident  venulitis
frequently requires antithymocyte globulin treatment (unpublished data) and represent
a more severe form of interstitial rejection. Furthermore, because of sampling error in
taking biopsies, vascular lesions at different sites in the graft could be missed.
In conclusion, the occurrence of CECs, ECs or both in peripheral blood is related
to CMV antigenemia and CMV-associated clinical symptoms. Transplant rejection
mechanisms  and  CMV  infection  have  a  cumulative  effect  on  the  release  of
endothelial cells. Many studies have shown that both CMV infection and acute
rejection are risk factors for chronic transplant failure [15]. With these data we
demonstrate that multiple injury in the first weeks after transplantation has cumulative
effects at the endothelial cell surface, which may predispose these patients toward
chronic graft failure.Chapter 9 124
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ABSTRACT
In 445 consecutive liver transplant recipients we observed lower platelet counts in
patients  with  cytomegalovirus  (CMV) infection.  This  significant  difference  in
platelet counts (27x10
3/mm
3, P < 0.05)  between patients  with and without CMV
infection was already observed on day 24 postoperatively; 6 days before we observed
CMV antigenemia. Leukocytes  also were lower in  patients  with CMV infection
(difference 1.7 x10
3/mm
3, P < 0.05) but this difference was observed later (mean day
36  postoperatively).  Apparently  the  fact  that  platelet  counts  diverge so  early
compared to CMV antigenemia and leukocytes points to  early systemic effects of
CMV  on  platelet  kinetics.  Considering  the  extensive  evidence  published  on
endothelial activation by CMV, we speculate that early relative thrombocytopenia
reflects CMV-induced endothelial activation.Platelets and CMV 129
10.1  INTRODUCTION
Cytomegalovirus (CMV) infection is a frequent  complication  after  solid organ
transplantation. Most patients with symptomatic CMV infection have a self-limiting
CMV syndrome consisting of malaise with fever and arthralgia. If no CMV prophyl-
axis is given CMV infection typically occurs 4 weeks after  transplantation  [1]. In
symptomatic patients leukocytopenia, thrombocytopenia and elevated serum liver
enzymes have been described. Due to prophylactic or  pre-emptive  therapy  with
ganciclovir lethal CMV infection is rarely seen nowadays. However CMV infection
is not without long-term consequences, since CMV is believed to play an important
role in the development of atherosclerosis, the  most important  cause of death in
transplant recipients [2, 3, 4]. Although mild thrombocytopenia is well established
as a symptom of CMV infection in transplant recipients, there  are no studies that
have systematically studied the changes in platelet count during CMV infection after
liver transplantation. Platelet counts are known to decrease in  many  acute  viral
diseases and platelets are known to be involved in diseases characterized by acute and
chronic endothelial activation. In the current study the  chronology  of changes in
platelet count, leukocyte count and CMV infection were studied in liver transplant
recipients with and without CMV infection.
10.2  METHODS
All orthotopic liver transplantations performed in our center between June 1992 and
July 2002 were analyzed. With regard to the incubation period of CMV, retransplant
procedures within 1 month of the first transplant were counted as a single transplant
episode.
The presence of CMV infection was diagnosed and monitored by the pp65 CMV
antigenemia assay [5-9] performed weekly, starting on postoperative day 10 until 12
weeks after transplantation or until CMV antigenemia  became negative.  Briefly,
peripheral blood leukocytes were isolated, cytocentrifuged and incubated with a
mixture of monoclonal antibodies directed against a 65 kD CMV antigen, followed
by immunoperoxidase staining. The number of antigen-positive  cells  and  total
number of leukocytes were counted on two different cytospots and results were ex-
pressed as the number of pp65 positive cells per 50.000 leukocytes.   
Recipient CMV-status before transplantation was assessed with CMV-IgG titers.
IgM and IgG CMV antibodies were measured quantitatively by ELISA using late stageChapter 10 130
CMV-infected fibroblasts as antigens [9]. Primary CMV infections  were defined as
infections in seronegative recipients receiving a transplant from a seropositive donor
(pos-neg donor-recipient serology combinations). Secondary CMV infections were
defined  as  infections  in  seropositive  recipients  (pos-pos or  neg-pos serology
combinations).
Before  1997  high-risk  patients  (i.e.  pos-neg)  received  prophylaxis  with
acyclovir; as off 1997 ganciclovir was given. High-dose ganciclovir or foscavir was
started in patients who developed CMV antigenemia.
Mean platelet count and leukocyte count were calculated at 2 day intervals for
all patients. All CMV antigenemia levels were analyzed between day 0 and day 100,
platelet counts and leukocyte counts were analyzed between day 0 and day 50 post-
operatively. In order to avoid bias by more frequent determinations of platelet count
or leukocyte count in some (e.g. sicker) patients, multiple measurements on the same
day were averaged to one value before further analysis. Likewise missing platelet
counts or leukocyte counts were interpolated.
Data are expressed as mean ± SEM, unless indicated otherwise. Differences were
assessed using Student’s t-test and were corrected according to Bonferroni in case of
multiple comparisons.Platelets and CMV 131
10.3  RESULTS
All 461 consecutive liver transplants  performed in our center  in the  study period
were analyzed. After combining early retransplants with previous transplants,  445
transplant cases remained. Median age of the  recipients was 34 years (range 0-68
years), 52% were males.
Of the 445 cases 208  (47%) had CMV infection  as diagnosed by a positive CMV
pp65-antigenemia assay. Within  these 208  patients  119  (57%) had low maximal
antigenemia  levels  (CMV  antigenemia  £ 10  positive  granulocytes/50.000
leukocytes), 58 (28%) moderate antigenemia levels (CMV antigenemia between 10
and 100) and 31 (15%) high levels (CMV antigenemia ≥ 100 positive granulocytes/
50.000  leukocytes)  (table  10.1).  28%  were primary  and  71%  were secondary
infections. CMV infection was detected at a mean of 30 days after transplantation.
A  significant  difference  in  the  platelet  counts  was  found  from  day  24  after
transplantation, with a platelet count that was 27x10
3/mm
3 lower in patients  withChapter 10 132
CMV compared to negative patients (P < 0.001, figure 10.1). This difference was due
to a lack of further increase in platelet count in patients with CMV infection. In fact,
mean platelet count in the CMV antigenemia positive patients remained within the
normal range. Absolute thrombocytopenia (i.e. < 50x10
3/mm
3) was seen in 19% of
the CMV antigenemia positive patients compared with 16% of the CMV antigenemia
negative patients (n.s.).
Subgroup analysis of the recipient serology status had no effect on the time course
of the platelet count for patients with or without CMV-infection. In contrast to the
platelet count, the leukocyte count in the two groups did not differ until day 36, after
which values became significantly lower in CMV positive  patients,  with a mean
difference of 1.7x10
3/mm
3 (P < 0.05, figure 10.2).Platelets and CMV 133
10.4   DISCUSSION
In this  study we observed significantly  lower platelet  counts  in  liver  transplant
recipients with CMV infection compared to liver transplant recipients without CMV
infection. The difference in platelet counts could already be observed several days
before onset of  a detectable CMV infection.  We  also observed lower leukocyte
counts, but this was observed 12 days later than the lower platelet counts.   
During the first days after liver transplantation early thrombocytopenia can be found
in the majority of patients [11]. Rapid increase of platelet count occurs towards the
end of the first week and a stable platelet count, within the normal range, is normally
achieved within 3-4 weeks [12]. Several factors play a role in the  development  of
this early thrombocytopenia after liver transplantation.  Massive blood loss during
the operation and disseminated intravascular coagulation probably play a role. An at-
tractive hypothesis for the pathogenesis of early thrombocytopenia is the sequestra-
tion of thrombocytes in the sinusoids of the liver by endothelial activation immedi-
ately after reperfusion of the liver [13, 14]. Platelets sequester in the liver immediate
after reperfusion and induce apoptosis of sinusoidal endothelial cells [14].  Platelet
sequestration  in  the  liver  correlates  with  the  duration  of  cold  ischemia  [15].
Upregulated adhesion molecules such as selectins play  an  important  role  in  the
adhesion of platelets to endothelial cells immediately after reperfusion. For example
platelet sticking can be reduced by inhibition of selectin receptor-mediated adhesion
by sialyl Lewis X oligosaccharide (sLe
x) [13].
We did not find a relation between CMV infection and early thrombocytopenia.
However after postoperative day 24 we observed a difference in platelet counts be-
tween patients with and patients without cytomegalovirus infection. This difference
is caused by a greater increase in platelet counts in the patients without CMV infec-
tion compared with patients with CMV infection. The difference in platelet counts
was seen 6 days before the CMV antigenemia assay became positive. Also the leuko-
cyte counts were lower in patients with CMV infection, but this difference appeared
later at a mean of 36 days postoperatively.
The kinetics of these events is interesting. Apparently CMV has an effect  on
thrombocytes before we can detect the  virus in blood with the  pp65-antigenemia
assay. The same may be the case with other assays like nucleic acid sequence-based
amplification (IE1-NASBA) [16, 17]. This indicates that CMV infection is an early
phenomenon after transplantation,  and that  dissemination via the  blood, and the
appearance of antigenemia or viral mRNA in blood, are relatively late. What we can
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berg, since it is an incomplete reflection of the pathophysiological process that takes
place [18, 19].
We can speculate on the pathophysiological mechanisms explaining the lower
platelet levels. In our opinion, infection of endothelial cells takes place after reac-
tivation of the virus. Subsequent to infection of endothelial cells, CMV can spread
hematogenously to different parts of the body. Circulating cytomegalic endothelial
cells probably play an important  role in the  spreading of the  virus. Polymorpho-
nuclear leukocytes take up pp65 from the infected endothelial cells. The pp65 anti-
genemia assay will become positive and reflects the  endothelial viral load. Before
appearance of pp65 positive leukocytes in the blood, infection of endothelial cells
has already begun and can affect thrombocytes. For example there is evidence that
Cytomegalovirus infection can induce tissue factor  on the  endothelial cell surface
[20, 21, 22]. Tissue factor is a main activator of the clotting cascade. Moreover, the
viral envelope contains  tissue factor  and procoagulant  phospholipids  that  cause
activation of the clotting cascade even before viral proteins are synthesized [23, 24].
Furthermore CMV induces  the  release  of  Von  Willebrand  factor  (VWF)  from
endothelial cells. VWF is an essential bridging molecule for platelet aggregation and
adhesion and acts as a carrier for factor VIII increasing the  half-life of factor  VIII
five-fold [25, 26]. Additionally CMV-induced adhesion molecules can augment the
adhesion of platelets to infected endothelial cells very early during CMV infection
[27].
Besides sequestration of thrombocytes due to activation of the clotting system
or by interaction with endothelial cells, decreased production of platelets is  con-
ceivable. For example decreased production of thrombopoetin  has been suggested
[28, 29]. Thrombocytopenia as shown in our study is a very early phenomenon  in
CMV infection and a decrease in production of thrombopoetin takes time to  have
effect in decreasing thrombocyte counts. Thus a  CMV-effect on  thrombopoiesis
would point to an even earlier impact of CMV-infection after transplantation than
an effect on platelet clearance. 
10.5   CONCLUSIONS
This is the first large clinical study confirming that CMV infection in liver transplant
recipients is associated with significantly lower platelet  counts. This difference in
platelet counts between liver transplant recipients with and without CMV infection
was observed even before detectable CMV antigenemia and two weeks before dif-Platelets and CMV 135
ferences in leukocyte counts. Apparently CMV infection occurs very early and more
widespread than usually realized, and in blood we only recognize the tip of the iceberg
relatively late during the infection. Sequestration of platelets caused by increased
adhesion to infected endothelial cells and intravascular pooling may be responsible
for the early difference in platelet counts.   Chapter 10 136
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ABSTRACT
Although diagnosis of Cytomegalovirus (CMV) infections  and treatment  of CMV
disease with effective antiviral drugs  have  become  much  easier,  the  persistent
problem of CMV infection after solid-organ transplantation still requires solid know-
ledge of the pathophysiology of its clinical manifestations in order to minimize the
impact of CMV infections  in the  future. The  complex  symptomatology  of CMV
infection after solid-organ transplantation  is reviewed as well as some of the  new
theories attempting to explain the myriad of symptoms, seen after transplantation.Calling for Heracles? 141
11.1  INTRODUCTION
Although a range of reliable and accurate diagnostic tests as well as effective  anti-
virals is available, CMV infections remain a substantial clinical problem in modern
organ transplantation, even now at the close of this century.  Compared to  10-15
years ago, a substantial part of clinical problems caused by CMV have been solved.
For instance CMV-related deaths are now relatively rare in solid-organ transplanta-
tion, but new problems have emerged. Aside from the warning signs of resistance of
CMV to antivirals due to  increasing (prophylactic?)  use of those  drugs in modern
intensive immunosuppressive protocols, various complications have appeared in the
aftermath  of  transplantation,  some  of  which point  to  CMV as the  culprit.  For
instance, CMV may be involved in the  process of chronic transplant  dysfunction
(‘chronic rejection’) as reviewed by Lautenschlager [1] while others [2, 3] suspect a
role for CMV in case of accelerated coronary atherosclerosis found in patients with
CMV infection after heart transplantation. The necessity to solve old problems while
at the same time new nuisances emerge reminds us somewhat of the Greek legend of
the monster Hydra. According to this legend Hydra was a monster with nine heads
(the number varies), the center one being immortal. The  monster’s  haunt was the
marshes of Lerna near Argos. The destruction of Hydra was one of the 12 labors of
Heracles, which he accomplished with the  assistance of  his nephew Iolaus. The
problem with this monster was that if one of his heads was cut off, two grew in its
place. Therefore, Heracles decided to burn out the roots with firebrands and at last
severed the immortal head from the body. So, to overcome new problems attributed
to CMV after solving old ones, we probably need a solution such as that used by
Heracles in the legend. However, as we do not appear to be on the verge of evolving
a method of killing the virus in its latent state (‘the immortal head’) without causing
lethal damage to its host,  CMV infections  will remain a problem in clinical solid-
organ  transplantation.
11.2  RISK FACTORS FOR CMV DISEASE
As far as symptomatology of CMV infection is concerned it  is  known  that  a
substantial part of patients with an active CMV infection is asymptomatic. Risk fac-
tors for CMV disease are well recognized and include the following: transplanting  a
CMV-seronegative patient with a CMV-seropositive donor organ (leading to a pri-
mary infection) and the recipient’s net state of immunosuppression, determined byChapter 11 142
the characteristics of the immunosuppressive protocol (type, dose, duration, timing)
and various host factors (co-morbidity, age, uremia, neutropenia, infections  with
other immunomodulating viruses) [4]. Bruning et al. [5] suggested an additional im-
portant role of allostimulation by the graft in the process of reactivation of CMV in
a rat model.
As far as the  type  of  immunosuppression is concerned,  especially antilym-
phocyte antibodies and monoclonal antibody preparations  such as OKT3  are well
known to cause a high incidence of CMV disease when used for either  induction or
anti-rejection therapy. While the immunosuppressive potency of this class of drugs
is usually suggested as the explanation for this high incidence of infection, other me-
chanisms might be involved. Recently a novel mechanism of reactivation has been
proposed: the proinflammatory cytokine TNF-a has been suspected to play a role
in the reactivation of  CMV by stimulation  of  the  CMV major  immediate  early
enhancer/promoter [6, 7, 8]. Since the use of OKT3 is well known for its abundant
cytokine release (i.e. TNF-a) this might explain the high incidence of active CMV
infection during OKT3 treatment. Finally, viral load might be an important factor.
Several authors stress the importance of a high viral load in relation to  the  risk of
clinical relevant CMV disease [4, 9-13].
11.3   SYMPTOMATOLOGY
Although in the era of rapid diagnostic tests for CMV and effective  antivirals one
might expect that the effect of CMV would fade away, CMV infections still have a
substantial impact on graft and patient survival in solid-organ transplantation [4, 9,
14-22]. Of all patients who develop clinical manifestations of CMV infection more
than 90% do so within 1-6 months  after  transplantation,  and 60% of the  febrile
episodes during this period are due to CMV infections [4, 9]. Because of more potent
immunosuppression used nowadays (with induction schemes including monoclonal
and polyclonal anti-T-cell antibodies), the timetable  of  infectious  complications
after transplantation tends to ‘shift to the left’ [4], resulting in earlier appearance
of clinically significant CMV infections. When patients are symptomatic, symptoms
may vary greatly. Most of the  patients  have a so-called ‘self-limiting syndrome’,
consisting of fever (often spiking), arthralgia, leukopenia and/or thrombocytopenia,
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With tapering of the immunosuppressive therapy, the great majority of patients
recover completely from the syndrome. Aside from  this  self-limiting syndrome,
CMV may cause a myriad of symptoms in the grafted patient. Gastrointestinal symp-
toms during CMV infections are numerous. They include gastrointestinal ulcers that
may bleed or perforate (i.e. gastric and colonic ulcers) [4, 9, 23-28]. CMV associated
vasculitis might be the common pathogenetic mechanism of this manifestation  of
the CMV syndrome in the immunocompromised patient [29]. Other gastrointestinal
symptoms  comprise  pancreatitis  [4,  9],  granulomatous  hepatitis  [30]  and
pneumatosis intestinalis [4, 9]. The latter condition is of particular interest because
the cysts may perforate, causing a sterile pneumoperitoneum. As a consequence, free
air may be present under the diaphragm on chest X-ray; the awareness of  the
association of this condition with an active CMV infection may avoid unnecessary
surgical intervention [31, 32]. Gastrointestinal symptoms may be present  without
other major symptoms of infection, and CMV may be present in the gastroduodenal
tract without symptoms.
Franzin et al. [33] found evidence of CMV inclusion bodies in biopsies collected
from the gastroduodenal mucosa of patients  with a renal allograft in 9 out of 20
cases. The presence of these CMV inclusions was unrelated to  viremia-induced or
gastrointestinal symptoms at the time of endoscopy [33]. Several other symptoms
have been attributed to CMV: lymphadenopathy, hepatosplenomegaly, pericarditis,
myocarditis, encephalitis, retinitis, and skin ulcerations associated with vasculitis [4,
9, 34, 35]. CMV-induced Guillain-Barré syndrome is a well-known phenomenon [36]
and is seen relatively frequently in AIDS patients but is a rarely encountered sequel
of an active CMV infection in transplanted patient. In AIDS patients direct infection
of the nerves  has been suggested to  play  a role  in  the  pathophysiology  of  the
syndrome, as well as autoimmune phenomena elicited by the virus [37, 38]. The
reasons why the incidence of this condition differs so greatly between the AIDS- and
the transplanted population are unknown,  but one  may  speculate about the  sig-
nificance of some overt differences that exist between the two groups. For instance,
although AIDS patients are also immunosuppressed, the nature of this suppression
differs considerably, which might reflect differences in sequelae leading to a possible
autoimmune process elicited by the virus. Another item that might be important in
order to explain the  dissimilarity is the  duration of viremia. In contrast  to  AIDS
patients, in whom prolonged CMV viremia is the rule, duration of viremia is usually
short in transplanted patients, being mostly confined to the period of  maximum
immunosuppression, i.e. shortly after initiation of anti-rejection therapy. One might
speculate about the importance of prolonged viremia as a prerequisite for the devel-
opment of autoimmune phenomena. If the latter is true this might be an importantChapter 11 144
clue in the pathophysiology  of a patient  characterized by an unusually prolonged
period of CMV viremia, very recently described by De Maar et al. [38]. This patient
presented with a chronic inflammatory  demyelinating polyneuropathy  after  renal
transplantation during recurrent CMV viremia. It is important,  however, to  stress
that great caution should be exercised in designating CMV as the culprit in case of a
given symptom: a single positive laboratory test may be not enough to consider the
symptoms present as induced by CMV. Other possible causes must be excluded and
laboratory signs for CMV infection have to be judged in concert with other signs of
CMV infection.
CMV pneumonia after solid-organ transplantation is the manifestation that dis-
tinguishes serious illness from the more benign disease, and the condition is associated
with high mortality, especially when assisted ventilation is required [4, 9,  39].
However, although still feared in the bone marrow transplantation, with the  emer-
gence of rapid diagnostic tests and the availability of effective prophylactic schemes
as well as effective antivirals to treat CMV infection in an early stage, the incidence
of CMV pneumonia has dramatically dropped.
Renal involvement during CMV infection remains controversial as far as patho-
genesis is concerned. It has been suggested that  CMV could trigger the  immune
mechanism of acute rejection either via i.e. increased MHC class II expression in the
graft or via mimicry, since CMV was shown to have sequence homology and immun-
ologic cross-reactivity with the HLA-DR b-chain [40, 41]. More recently Reinke et
al. [42] described a series of patients with asymptomatic CMV infections which they
linked with late acute rejection.
Alternatively, in 1981, Richardson et. al. [43] described a distinctive pattern  of
glomerular injury in renal allografts that they associated with CMV viremia without
relation with allograft rejection. The pathological features consisted of diffuse endo-
thelial hypertrophy and necrosis, accompanied by an accumulation of fine fibrillar
webs of periodic-acid-Schiff (PAS)-positive  material  and mononuclear  cells that
resulted in obliteration of the glomerular capillaries. Fibrin, IgM as well as C3 were
found by immununofluorescence. No viral particles were detectable by electron
microscopy of immunofluorescenc using monoclonal antibodies directed to CMV ear-
ly and late antigen [43].
The existence of this condition has been disputed by Herrera et al. [44]  and
Boyce et al. [45] who consider it to be  a form  of  (vascular type  or  ‘transplant
glomerulopathy’) rejection.
Aside from the directly  attributable  syndromes there  are  important  indirect
effects of CMV in the compromised host. CMV has important  immunomodulating
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a given patient, making him or her prone  to  superinfections with i.e. Aspergillus
species and Pneumocystis carinii [4, 9, 46].
In a recent multicenter study by the Boston Center for Liver Transplantation
a multivariate analysis showed that patients with CMV disease had significant more
invasive fungal disease and bacteremia [47].
11.4  PATHOFYSIOLOGY OF CMV INFECTION
How CMV causes symptomatology and organ dysfunction in the recipient is still
rather enigmatic and the subject of much debate and research. The question  is
whether symptomatology is caused by the cytopathic effect of the virus itself or is
brought about by the (innate as well as specific) immune response elicited by the virus
or virus infected cells (i.e. endothelial cells). On the one hand a clear relation exists
between the viral load and the likelihood and the severity of CMV disease [4, 9-12],
but on the other hand it has been  known  for  years  that  notably  the  number of
antigen-positive leukocytes (pp65 antigenemia), which has been shown to correlate
well with viral load [48], is not always a reflection of the virtual severity of the
clinical situation. The question remains unanswered whether this discrepancy is
caused by a high viral load with a less virulent virus or a more mitigated immune
response to the same virus. For instance there  exists a lot of data indicating that
virus-induced pneumonitis is not only the result of uncontrolled virus replication in
the immunocompromised host, who is unable to  control  viral  replication,  but is
rather the result of a T-cell-mediated immune response induced by viral antigens
[49]. So, the protean manifestations of CMV seen after solid organ transplantation
suggest that unrevealing of the pathophysiology will most likely reveal a very
complex and multifaceted mechanism. Is CMV-induced endothelial  cell  damage
(‘vasculitis’) -with or without secondary immune response directed to the infected
endothelial  cells- the key factor? The key role of the  endothelial  cell  in  the
pathophysiology is in agreement with the work of Persoons et al. [50]  using a rat
model. They found that in this infection model multiple-organ involvement  was
associated with disseminated vascular pathology.  CMV-infected endothelial  cells
might secondarily induce adhesion of leukocytes to the damaged endothelium [51],
trigger the coagulation system [52] and induce cytokines like IL6 [53] which might
contribute to the pathophysiology of CMV-induced multi organ disease. CMV also
infects endothelial cells of transplanted patients; these cells may even detach from
the vessel wall and subsequently be released in the  circulation [54].  In the  mono-Chapter 11 146
nuclear cell fraction of peripheral blood of a patient with a CMV infection after
heart transplantation Grefte et al. [54] unexpectedly found distinctly large cells (35-
45 mm diameter), reminiscent of the classical ‘cytomegalic inclusion body cells’. In
a subsequent study Grefte et al. [55] showed that those cells could be demonstrated
in a substantial part of patients with an active CMV infection after solid-organ trans-
plantation, especially in those with a high viral load in their blood. Immunostaining
revealed those cells to be endothelial cells positive for HCMV antigens of all three
stages of the viral replication cycle (with the typical  nuclear  and  cytoplasmic
localization of the distinct antigens) [54], while transmission electron microscopic
studies showed that viral capsids, viral particles and dense bodies were present in the
in the nucleus and cytoplasm, respectively, indicating that those cells represent a site
of virus production [55].
Whether those cytomegalic endothelial cells play a role in the dissemination of
the virus and/or organ dysfunction is far from settled, but it surely fits in with the
data obtained from animal models [50-53] that suggest a key role for the  CMV-
infected endothelial cells in the pathophysiology of CMV infection. CMV infection
may thus be looked on as a systemic disease with a multifaceted symptomatology. In
this respect, it is of interest that subclinical organ involvement can be demonstrated
in the majority of patients after organ transplantation even with an asymptomatic
CMV infection [56]. A majority of patients with an active CMV infection after renal
transplantation show subtle pulmonary dysfunction (decreased diffusion capacity for
carbon monoxide) without clinical pulmonary symptoms [56].  This may point  to
subclinical pneumonitis due to either a direct cytopathic  effect  of  CMV on  pul-
monary tissue, or to cellular immune response directed to  e.g. infected pulmonary
endothelial cells, with or without serum complement activation by the  classical or
alternate activation pathway [56, 57]. Another explanation  might  be that  large
cytomegalic endothelial cells 35-45 mm in diameter [54]  plug into  the  lung capil-
laries, which have a diameter of only 5 mm. This was subsequently studied by De Maar
et al. [58] using a method by which both components  of diffusion of CO could be
studied separately; the membrane factor Dm (i.e. affected by edema of the alveolar
membrane) and the capillary (‘blood’) factor Vcap, which is most likely to be
affected by plugging of those large cells into the capillary bed. We concluded from
this study that, since both Dm and the Vcap decreased during active CMV infection,
the decreased diffusion capacity for CO was not caused by plugging of  the  cyto-
megalic endothelial cells only [58]. Other factors might be involved: i.e. since they
contain active replicating virus [54, 55], the cytomegalic endothelial cells may lead
to spreading of the  virus into  the  capillary bed which in turn together  with com-
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cause edema of the alveolar membrane and hence to the decreased Dm found in these
patients [58]. Recently, we have also shown subclinical involvement of the gastro-
intestinal tract [60]. Increased intestinal permeability indicating intestinal epithelial
damage has been found in a substantial number of  patients  with an  active  CMV
infection after renal transplantation [60]. Although this also points towards a more
systemic nature of CMV infections, the exact reasons for those findings still have to
be elucidate.
11.5   SUMMARY AND CONCLUSIONS
Even in modern transplantation, with the availability of rapid diagnostic tests and
effective antiviral drugs, CMV infections remain the single most important infectious
complication after solid-organ transplantation. In the last decade much has  been
learned about its pathophysiology, although it requires  much  more  thought  to
comprehend the exact mechanism of the protean manifestations of CMV infection
after organ transplantation. Since we continue to meddle in the inevitable marriage
between CMV and host immunity, introducing new, non-selective immunosuppressive
drugs, we probably need a ‘Heracles-like’ solution for solving the CMV problem in
modern transplantation. Since it is very unlikely that anti-CMV drugs will become
available in the near future to  influence the  latent  state  of this virus by nontoxic
means, CMV will remain a serious problem, even at the dawn of the new millennium.Chapter 11 148
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FINAL CONCLUSIONS
Cytomegalovirus  infection  is  it  still  important  in  the  transplant  clinic?  Is
cytomegalovirus a vanishing or changing problem?  The  aim  of  this  thesis  is to
elucidate  the  pathofysiological  processes  that  play  a  role  in  the  protean
manifestations of cytomegalovirus infection after organ transplantation.
In chapter 1 a general introduction is given. In chapter 2 we describe the course of
CMV infection frequencies in our transplant center the last ten years. We describe
that modification of our immunosuppressive regimen, switching from cyclosporine
standard formulation (Sandimmune, Novartis) to microemulsion formulation (Neoral,
Novartis),  and  later  adding  mycophenolate  mofetil  (Cellcept,  Roche)  was
accompanied by an increased incidence of secondary CMV infections.  Also  we
noticed higher and more prolonged CMV viremia especially after the addition of
mycophenolate mofetil to our immunosuppressive regimen. However, owing to bet-
ter antiviral therapy and better monitoring, most CMV infections are asymptomatic
nowadays. Mortality as well as morbidity associated with CMV is low. Is the increased
incidence  and  prolonged  viremia  of  CMV  infections  clinically  irrelevant?  Is
cytomegalovirus infection still an important issue after kidney transplantation?  A
related question can be posed on the subject of acute rejection. Is it still important
after transplantation? As a result of better immunosuppressive drugs the  incidence
of acute rejection is small in most of the  large multicenter  studies. In my opinion
acute rejection and CMV infection  are still important.  Although the  incidence of
acute rejection has decreased in most centers, acute rejection is still a significant
problem. As to this latter statement, the increased acceptance of non-heartbeating
donors might be one of he factors explaining why the incidence of acute rejection is
still considerable. The acceptance of this category of donor organs comes along with
an increased incidence of delayed graft function, primary  non-function, and a higher
incidence of acute rejection. If one tries to decrease the incidence of acute rejection
the benefit of more potent immunosuppressive therapy has to be weighed against an
increased incidence of viral infections and malignancies after transplantation.  The
increased incidence of CMV infections, the longer duration and higher viral load may
be detrimental on the long run. Also asymptomatic infections that are supposed to
be ‘innocent’ might have influence on graft and patient survival.Chapter 12 156
In the following chapters we describe that patients with asymptomatic so-called ‘in-
nocent’ CMV infection indeed have subclinical organ dysfunction. These infections
are asymptomatic but we demonstrate that they do cause damage and this might have
consequences on the long term.
In chapter 3 we describe that a significant number of patients with active CMV
infection after renal transplantation have increased intestinal permeability indicating
intestinal epithelial damage. This finding does not provide a useful marker of CMV
infection, but it gives insight into the  pathofysiology  of the  widespread even sub-
clinical manifestations of CMV infection after transplantation. In my opinion  the
epithelial damage is an early, subclinical stage in the development of CMV ileitis or
gastrointestinal ulcers.
In chapters 4, 5  and  6 we investigate  the  pulmonary  dysfunction  found in
patients with CMV infection. As noticed earlier by van Son et al. (Transplantation
1987; 44:149) pulmonary diffusion is decreased in renal transplant patients  with
CMV infection. This was attributed to complement activation and plugging of leuko-
cytes. Some years later  Grefte et  al. (The  Journal of  Infectious  Diseases 1993;
167:270) found large cytomegalic endothelial cells (CECs; diameter 30-35 mm) in the
peripheral blood of patients with CMV infection. We hypothesized that these large
cells could cause the pulmonary diffusion disturbances by plugging in the capillary bed
of the lungs. However in chapter 4 we describe that the decrease in lung diffusion in
renal transplant recipients with CMV infection was due to both a lower capillary
volume as well as a lower membrane factor. This is an argument against just plugging
of CECs, because plugging would predominantly cause a lower capillary volume. In
chapter 6 we describe that the pulmonary diffusion capacities between patients with
and without CEC were similar. Also no  tendency  towards a diminished capillary
volume was observed in patients with CECs, although numbers were small. Because
the  occurrence  of  CECs  is  strongly  related  to  high  CMV  antigenemia  levels,
reflecting a higher viral load, we analysed the severity of infection, as indicated by
CMV antigenemia levels, in relation to CO diffusion as well. Patients were stratified
into two groups with high CMV antigenemia levels and moderate to low antigenemia
levels. In the high CMV antigenemia group, the  membrane factor  decreased more
than in the group showing low CMV antigenemia. This represents increased diffusion
resistance in the patients with high antigenemia levels. An inflammatory  reaction
with production of cytokines, fluid extravasation  and cellular infiltrate  probably
underlies these findings. A logical consequence of the inflammation might be that the
lungs are more susceptible to  other  opportunistic  infections.  Possible long-term
consequences of CMV infection on pulmonary function need to be investigated.Final conclusions 157
In chapter 9 and 10 we address another important effect of CMV infection for
the patient and his graft. We demonstrate the relation between CMV and the endo-
thelium. In chapter 9 we describe the detection of CECs in patients with CMV infec-
tion with high or moderate antigenemia levels. Non-infected circulating endothelial
cells (ECs) were even observed in all patient categories independent of the severity
of infection. Significantly more CMV-associated clinical symptoms  were found in
patients with CECs or ECs. Patients with rejection episodes preceding CMV infection
had increased frequencies of CECs or ECs. The type of rejection was not significantly
related to the detection of endothelial cells, but a tendency could be observed to
higher frequencies in patients with vascular or steroid resistant interstitial rejection.
We conclude that CMV infection, especially in combination with vascular or steroid
resistant rejection and also the perseverance of viral load  (chapter  2), results in
extended endothelial damage, and may contribute to  the  development  of chronic
transplant failure and atherosclerosis even in asymptomatic patients. Many studies
have shown both CMV infection and acute rejection to be risk factors for chronic
transplant failure. With our data we demonstrate that rejection and CMV infection
in the first weeks after transplantation have cumulative effects at the endothelial cell
surface, which may predispose  these  patients  toward  chronic  graft  failure  and
atherosclerosis.
In chapter 10 we describe that CMV infection  in liver transplant  recipients is
associated with significantly lower platelet counts. The lower platelet counts in liver
transplant recipients with CMV infection, compared to  liver transplant  recipients
without CMV infection, was already observed several days before detectable CMV
antigenemia. Infection of endothelial cells is an early and central phenomenon during
CMV infection. Subsequent to  infection  of  endothelial  cells,  CMV can  spread
hematogenously to different parts of the body. Circulating cytomegalic endothelial
cells  probably  play  a  role  in  the  spreading  of  the  virus.  Polymorphonuclear
leukocytes take up pp65 from the infected endothelial cells. Before appearance  of
pp65-positive leukocytes in the blood, infection of  endothelial  cells has already
begun and can affect thrombocytes. Apparently CMV infection occurs very early and
more widespread than usually realized. In blood we only recognize the tip of the
iceberg relatively late during the infection. Procoagulant properties of  CMV and
increased adhesion to endothelial cells may be responsible for the early difference in
platelet counts.
Symptomatic CMV infection is often a flu like syndrome with fever, arthralgia,
and in the blood tests leukocytopenia, thrombocytopenia and elevated liver trans-
aminases may be demonstrated. In  particular  in  patients  with long lasting CMV
infection, all organ systems can be involved. For example gastroenteritis,  ulcers,Chapter 12 158
vasculitis, pneumonitis and retinitis are seen. In chapter 8 we describe a patient with
a less frequently observed disease possibly related  to  smoldering CMV infection:
demyelinating polyneuropathy.
In this thesis I state that the endothelium plays a crucial role  in  the  patho-
fysiology of cytomegalovirus infection. First there is infection of endothelial cells
by the virus. There is a change in molecules on the  surface of infected endothelial
cells and neighbouring endothelial cells. This change can vary from downregulation
to upregulation of adhesion molecules and HLA molecules. These molecules cause
adhesion of leukocytes and thrombocytes to endothelial cells. The clotting system
is activated. Detachment of infected (CECs) and non-infected endothelial cells (EC)
can be demonstrated in the peripheral blood. The CECs most probably play a role in
the dissemination of CMV infection. In all organs clinical or subclinical dysfunction
can be demonstrated. In my opinion the endothelial damage is  important  in  the
development of organ dysfunction but also in the development of chronic transplant
dysfunction and atherosclerosis.
In conclusion CMV infection  is a changing problem. It is our goal to  further
elucidate the possible effects of CMV infection on long-term graft function and graft
survival in patients receiving more immunosuppression and having more and often
longer lasting CMV infection. This is a challenge.Final conclusions 159
Schematic clockwise presentation of CMV infection. At
twelve a clock endothelial cells become activated and
adhesion molecules are upregulated. This is caused by
CMV infection of the endothelial cells with grey nuclei at
three a clock. The endothelial cells become more
thrombogenic and relative thrombocytopenia develops. PMN
are polymorphonuclear granulocytes that take up the viral
protein pp65 from the infected endothelial cells at three a
clock. This results in a positive antigenemia assay. Mj is a
macrophage, NK is a natural killer cell, Tc is a cytotoxic T
cell, Th is a helper T cell and P is a plasma cell. Mj, NK, Tc,
Th, P, cytokines, immunoglobulins and complement play a
role in the defense against CMV. Infected endothelial cells
become cytomegalic and detach. At six a clock a circulating
cytomegalic endothelial is seen (CEC).  SMC are smooth
muscle cells that migrate and proliferate (induced by CMV)
and play a role in the formation of an atherosclerotic plaque
at 9 a clock. The inside of the clock symbolizes the organs
where pathology due to CMV infection is found.
Figure 12.1CHAPTER 13
SAMENVATTING
(Summary in Dutch)
Cytomegalovirus (CMV) is een herpesvirus net zoals het  veel  bekendere koorts-
lipvirus dat in de volksmond  herpes  heet.  Een  ander bekend voorbeeld van  een
herpesvirus is het varicella zoster virus (VZV) dat waterpokken  of gordelroos ver-
oorzaakt. Een belangrijke eigenschap van de herpesvirussen is dat ze na een infectie
niet door de patiënt uit het lichaam verwijderd worden. De herpesvirussen verstoppen
zich in de patiënt (‘latency’) en komen alleen tevoorschijn als de weerstand van de
patiënt afneemt. Deze weerstand bestaat uit ons afweersysteem met als verdedigers
onder andere de T-lymfocyten en de NK(killer) cellen. Bij het koortslipherpes
(HSV1) is er slechts een geringe afname van de afweer nodig om het  virus uit zijn
schuilplaats te doen komen. Bij forse aanslagen op ons afweersysteem zoals optreden
door  gebruik  van  afweeronderdrukkende  medicijnen  (immunosuppressiva  zoals
prednisolon, cyclosporine, cellcept, en antithymocytenglobuline) komt het CMV uit
zijn schuilplaats en kan de getransplanteerde patiënt ziek maken. Vaak krijgen deze
patienten dan een griepachtig beeld met koorts, malaise en gewrichtsklachten (kne-
kelkoorts). In principe kunnen alle organen aangetast worden door het virus. Er zijn
ook veel getransplanteerden die niet ziek worden van het virus ondanks dat het virus
wel uit zijn schuilplaats is gekomen en dus ook in het bloed van de patiënt  door
middel van een daarvoor ontwikkelde test aantoonbaar is (antigenemie-test).
Dit proefschrift begint met de bevinding dat CMV infecties bij niertransplantatie-
patiënten de laatste jaren toenemen en ook langer duren door sterkere afweeronder-
drukkende medicijnen (hoofdstuk 2). Deze immunosuppressiva zorgen  dus voor
minder afstoting (acute rejectie) enerzijds, maar dit gaat ten  koste  van een groter
aantal CMV infecties. Een belangrijk deel van dit proefschrift gaat erover dat bij
ogenschijnlijk niet zieke patiënten wel degelijk afwijkingen zijn te vinden in bijvoor-
beeld de darm en longen (hoofdstuk  3 en 4). Dit proefschrift  legt uit dat CMV de
bekleding (endotheel) van de bloedvaten infecteerd en de eigenschappen van  het
endotheel verandert. De diffuse aantasting van verschillende organen door CMV zou
verklaard kunnen worden door infectie of veranderingen van de eigenschappen van
de vaatwand. Geïnfecteerd endotheel kan ook loslaten van de vaatwand en daardoorChapter 13 162
bijdragen aan de verspreiding van het virus. Deze losgelaten geïnfecteerde cellen
lijken vooral uit de getransplanteerde nier te komen en er is een relatie met afstoting
in de nier (hoofdstuk 6). Het belang van de toename van het  aantal CMV infecties
ook  al  geven  ze  vaak  weinig klachten  is  de  mogelijke  relatie  van  CMV met
atherosclerose (vaatverkalking) en chronische transplantaat dysfunctie (chronische
afstoting). Deze relatie is te verklaren  door atherosclerose te beschouwen als een
gevolg van schade van de bekleding van de vaatwand. Deze schade kan ontstaan door
roken, cholesterol, hoge bloeddruk maar ook door  CMV infectie.  De chronische
transplantaat dysfunctie is voor een groot deel te beschouwen als atherosclerose en
daardoor zuurstofgebrek en schade in de tranplantatienier. Het zou best zo kunnen
zijn dat de toename  van  het  aantal  CMV infecties  uiteindelijk de lange termijn
overleving  van  transplantatienieren  en  ook  van  de  patiënten  verminderd.  Dit
ondanks korte  termijn  winst van  minder acute  rejecties  door  sterkere  immuno-
suppressiva. Het is dus van het grootste belang een goed evenwicht te vinden tussen
rejectie enerzijds en infectie anderzijds.PUBLICATIONS
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